Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine

3 "Patria" (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector

4 (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline

5 Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination

Constantino López-Macías^{1*}. Martha Torres². Brenda Armenta-Copca³. Niels H. 6 7 Wacher⁴, Arturo Galindo-Fraga⁵, Laura Castro-Castrezana⁶, Andrea Alicia Colli-Domínguez⁷, Edgar Cervantes-Trujano⁸, Isabel Erika Rucker-Joerg⁹, Fernando 8 Lozano-Patiño¹⁰, Juan José Rivera-Alcocer¹¹, Abraham Simón-Campos¹², Efrén 9 Alberto Sánchez-Campos¹³, Rafael Aguirre-Rivero¹⁴, Alejandro José Muñiz-10 Carvajal¹⁵, Luis del Carpio-Orantes¹⁶, Francisco Márguez-Díaz¹⁷, Tania Rivera-11 Hernández^{1,18}, Alejandro Torres-Flores^{1,19}, Luis Ramírez-Martínez²⁰, Georgina Paz-12 De la Rosa²⁰, Oscar Rojas-Martínez²⁰, Alejandro Suárez-Martínez²⁰, Gustavo 13 Peralta-Sánchez²⁰, Claudia Carranza², Esmeralda Juárez²¹, Horacio Zamudio-14 Meza², Laura E. Carreto-Binaghi², Mercedes Viettri², Damaris Romero-Rodríguez²², 15 Andrea Palencia², David Sarfati-Mizrahi²⁰, Weina Sun²³, Héctor Elías Chagoya-16 Cortés²⁴, Felipa Castro-Peralta²⁰, Peter Palese²³, Florian Krammer^{23,25,26}, Adolfo 17 García-Sastre^{23,26,27,28,29,30}, and Bernardo Lozano-Dubernard^{20*} 18

¹Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de 19 Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro 20 Social (IMSS), Ciudad de México (CDMX), México.²Laboratorio de Inmunobiología 21 de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) 22 "Ismael Cosío Villegas", CDMX, México. ³iLS Clinical Research, S.C., CDMX, 23 México. ⁴Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital 24 de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, CDMX, México. 25 ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), 26 CDMX, México. ⁶CAIMED Investigación en Salud, S. A. de C. V., CDMX, México. 27 ⁷Oaxaca Site Management Organization (OSMO) S.C., Oaxaca, México. ⁸Centro de 28 Investigación Clínica Acelerada (CICA), S.C., CDMX, México. ⁹Clinical Research 29 Institute (CRI) S.C., Edo. de México, México. ¹⁰Centro de Investigación Clínica 30 Chapultepec, CDMX, México. ¹¹Unidad de Atención Médica e Investigación en 31 Salud (UNAMIS), Yucatán, México. ¹²Köhler & Milstein Research (K&M) Facultad de 32 Medicina, Universidad Autónoma de Yucatán, Mérida, Yucatán, México. ¹³Centro 33 Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en 34 Yucatán (CEMDEICY) S.C., Yucatán, México.¹⁴Centro de Investigación Clínica del 35 Pacifico (CICPA), Guerrero, México.¹⁵Red OSMO, Centro de Investigación y 36 Avances Médicos Especializados (CIAME), Quintana Roo, México. ¹⁶Instituto 37 Veracruzano de Investigación Clínica (IVIC) S.C., Veracruz, México. ¹⁷Hospital de 38 Cardiológica Aguascalientes, Aguascalientes, México.¹⁸Investigadores por México, 39 Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), CDMX, 40 México.¹⁹Posgrado en Inmunología, Escuela Nacional de Ciencias Biológicas, 41

Instituto Politécnico Nacional, CDMX, México. ²⁰Laboratorio Avi-Mex S.A. de C.V., 42 CDMX, México.²¹Departamento de Investigación en Microbiología, INER "Ismael 43 Cosío Villegas", CDMX, México. ²²Unidad de Citometría, INER "Ismael Cosío 44 Villegas", CDMX, México. ²³Department of Microbiology, Icahn School of Medicine 45 at Mount Sinai, New York, NY, USA. ²⁴Consultora Mextrategy, S.A.S. de C.V., 46 CDMX, México. ²⁵Center for Vaccine Research and Pandemic Preparedness (C-47 VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. 48 ²⁶Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of 49 Medicine at Mount Sinai, New York, NY, USA. ²⁷Department of Medicine, Division of 50 Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 51 ²⁸Global Health and Emerging Pathogens Institute, Icahn School of Medicine at 52 Mount Sinai, New York, NY, USA. ²⁹The Tisch Cancer Institute, Icahn School of 53 Medicine at Mount Sinai, New York, NY, USA. ³⁰The Icahn Genomics Institute, Icahn 54 School of Medicine at Mount Sinai, New York, NY, USA. 55

*Correspondence: <u>lozano@avimex.com.mx</u> (B. Lozano-Dubernard),
 <u>constantino.lopez@imss.gob.mx</u> (C. López-Macías)

58 Abstract

Background: The urgent need for safe, effective, and economical coronavirus 59 disease 2019 (COVID-19) vaccines, especially for booster campaigns targeting 60 vulnerable populations, prompted the development of the AVX/COVID-12 vaccine 61 candidate. AVX/COVD-12 is based in a Newcastle disease virus La Sota (NDV-62 LaSota) recombinant viral vector. This vaccine expresses a stabilized version of the 63 spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 64 specifically the ancestral Wuhan strain. The study aimed to assess its safety, 65 immunogenicity, and potential efficacy as an anti-COVID-19 booster vaccine. 66

Methods: In a phase II/III clinical trial conducted from November 9, 2022, to 67 September 11, 2023, a total of 4.056 volunteers were enrolled. Participants received 68 an intramuscular booster dose of either AVX/COVID-12 or AZ/ChAdOx-1-S 69 vaccines. Safety, immunogenicity, and potential efficacy were assessed through 70 various measures, including neutralizing antibody titers, interferon (IFN)-y-producing 71 CD4+ T cells, and CD8+ T cells. The evaluation also involved immunobridging, 72 utilizing the AZ/ChAdOx-1-S vaccine as an active comparator, and monitoring the 73 incidence of COVID-19 cases. 74

Findings: The AVX/COVID-12 vaccine induced neutralizing antibodies against both
 the ancestral SARS-CoV-2 and the BA.2 and BA.5 Omicron variants. The geometric
 mean ratio of neutralizing antibody titers between individuals immunized with the
 AVX/COVID-12 vaccine and those with the AZ/ChAdOx-1-S vaccine at 14 days is
 0.96, with a confidence interval (CI) of 0.85-1.06. The outcome aligns with the non inferiority criterion recommended by the World Health Organization (WHO),
 indicating a lower limit of the CI greater than or equal to 0.67. Induction of IFN-γ-

producing CD8+ T cells at day 14 post-immunization was exclusively observed in
the AVX/COVID-12 group. Finally, a trend suggested a potentially lower incidence
of COVID-19 cases in AVX/COVID-12 boosted volunteers compared to AZ/ChAdOx1-S recipients.
Conclusion: The AVX/COVID-12 vaccine proved safe, well-tolerated, and

immunogenic. AVX/COVID-12 vaccine proved sale, weil-tolerated, and
 immunogenic. AVX/COVID-12 meets the WHO non-inferiority standard compared to
 AZ/ChAdOx-1-S. These results strongly advocate for AVX/COVID-12 as a viable
 booster dose, supporting its utilization in the population.

KEYWORDS: COVID-19 vaccine, Phase II/III clinical trial, Newcastle disease virus
 LaSota, SARS-CoV-2.

92 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants of
 concern have caused hundreds of millions of infections and millions of deaths around
 the globe since 2020 (1).

At the beginning of 2021, anti-SARS-CoV-2 vaccination campaigns had been launched in almost 200 countries with more than 13.53 billion doses distributed (2); as of November 2022, emergency use approval has been granted to 50 vaccine candidates (3). These vaccines have shown to be effective in phase III clinical trials and to induce neutralizing antibodies that target the spike protein of SARS-CoV-2 among other antigens less studied (4). In addition to the vaccines already in use, many other candidates are in a preclinical or clinical development.

103 Despite the remarkable speed in the development of coronavirus disase 2019 104 (COVID-19) vaccines since 2020, there have been over 6.9 million official deaths 105 from COVID-19 (1) (with estimates based on excess mortality being 3-4 times higher). Moreover, the unequal global distribution of vaccines, particularly impacting 106 107 low- and middle-income countries (LMICs), underscores the urgency for the continued development of new vaccine platforms to address disparities in 108 distribution. Ensuring a high vaccination rate worldwide is crucial for reducing the 109 likelihood of new variant emergence. Additionally, the administration of periodic 110 booster doses is essential to prevent subsequent waves of COVID-19 and safeguard 111 vulnerable populations, including the elderly, immunocompromised individuals, and 112 113 those with comorbidities. Consequently, the global vaccine supply remains an urgent issue that requires attention (5). 114

The AVX/COVID-12 vaccine candidate is a Newcastle disease virus LaSota (NDV-LaSota) vector-based vaccine that expresses the HexaPro version (6 prolines that stabilize the prefusion conformation) of the SARS-CoV-2 spike protein (6,7).

Among the main advantages offered by the NDV-LaSota vector is the standardized production process in embryonated chicken eggs, easy to develop in existing facilities for the manufacture of influenza vaccines, achieving the production of large numbers of doses in a short time (8). Therefore, this could help to fulfill vaccine
demand, particularly in countries with a low immunization rate or incomplete
vaccination scheme.

124 The NDV-LaSota vector, expressing the spike protein of the SARS-CoV-2 virus, has 125 demonstrated efficacy in preclinical studies, particularly in mice and hamsters. 126 Following intranasal (IN) immunization in mice, the generation of IgA and IgG2a 127 antibodies, with a response of IFN- γ -producing T cells, was observed. This vector 128 provided complete protection against infection in mice and hamsters, indicated by 129 the absence of viral titers and viral antigen in the lungs of mice and a significant 130 reduction in SARS-CoV-2 shedding in hamsters (8,9).

- Preclinical trials involving pigs were conducted in Mexico to assess the safety and 131 132 immunogenicity of the AVX/COVID-12 vaccine when administered via intramuscular (IM) or IN routes. The study revealed robust responses in serum-neutralizing 133 antibodies, with notable reactivity to variants of concern (VOCs) carrying mutations 134 in the spike protein epitopes (10). In a Phase I clinical trial (NCT04871737) with 91 135 volunteers, the vaccine was evaluated with various booster regimens administered 136 through both IM and IN routes, demonstrating significant immunogenicity in both 137 cases. The safety of this vaccine was also confirmed in these studies, establishing 138 139 the foundation for further clinical development (11).
- Similar vaccines are undergoing clinical trials, with a live version being tested in the 140 United States (NCT05181709), whereas inactivated vaccines based on the same 141 vector are also in clinical testing, with ongoing trials in Vietnam (Phase I 142 NCT04830800), Thailand (Phase I/II NCT04764422, Phase III TCTR20221026004), 143 144 and Brazil (Phase I NCT04993209 and Phase II/III NCT05354024). Available reports indicate favorable safety and immunogenicity profiles for these vaccines (12-14). 145 Recently, an inactivated version of this vaccine was authorized for emergency use 146 as a booster for the prevention of severe COVID-19 in Thailand (15). 147
- In Phase II clinical trials, the AVX/COVID-12 vaccine underwent assessment through 148 149 both IM and IN administrations as a booster dose. The study demonstrated safety and immunogenicity via both routes in volunteers who had previously received 150 mRNA. AZ/ChAdOx-1-S. or inactivated virus vaccines or were infected with SARS-151 CoV-2, all of whom initially exhibited anti-spike IgG titers below 1,200 units (U)/mL 152 in a chemiluminescence test. AVX/COVID-12 IM or IN immunization induced a 153 significant (\geq 2.5 fold) increase in the neutralizing antibody response against SARS-154 CoV-2 variants of concern by day 14, despite expressing the original Wuhan-1 strain 155 spike protein. Noteworthy elevations in neutralizing antibodies against multiple 156 variants of concern, including Alpha, Beta, Delta, and Omicron (BA.2 and BA.5), 157 were observed when compared to the placebo groups (16). 158

In this phase II/III parallel study, we investigated the safety and immunogenicity of a
 single intramuscular booster dose of AVX/COVID-12 in healthy adults with a history
 of prior COVID-19 vaccination and/or SARS-CoV-2 infection. Unlike in the Phase II

trial, participants were included irrespective of their initial anti-S antibody levels. 162 163 Given the pandemic situation during the recruiting period of the trial (Figure 1S), enrolled individuals exhibited a wide range of baseline antibody titers. Additionally, 164 we conducted an active-controlled non-inferiority study (immunobridging) using the 165 AZ/ChAdOx-1-S vaccine as the comparator, as both are vectorized vaccines. The 166 AZ/ChAdOx-1-S vaccine has proven to be safe and effective against SARS-CoV-2 167 infection, demonstrating an effectiveness of 84.3% against asymptomatic SARS-168 CoV-2 infection and 98.9% against COVID-19 hospitalization (17,18). Moreover, it 169 170 has become the most widely used vaccine globally, deployed in 185 countries since its approval for emergency use (19). In Mexico, since November 2021, more than 171 79.43 million doses have been administered, covering single-dose, full vaccination, 172 and booster regimens, utilizing both homologous and heterologous systems (20). 173 The characteristics of AZ/ChAdOx-1-S make it a suitable comparator for testing 174 AVX/COVID-12 in a non-inferiority trial. 175

176 Material and methods

177 Study design

A phase II/III double-blind study (ClinicalTrials.gov #NCT05710783) was conducted 178 to assess the safety, immunogenicity, and post-boosting incidence of SARS-CoV-2 179 infection following a single IM dose of SARS-CoV-2 vaccine (AVX/COVID-12) 180 "Patria". The primary objective was to establish non-inferiority in the SARS-CoV-2 181 neutralizing antibodies production at day 14 post-administration by comparing it with 182 an active control, the AZ/ChAdOx-1-S vaccine. Randomization involved the 183 administration of a single IM dose of the experimental AVX/COVID-12 vaccine at a 184 concentration of 10^{8.0} tissue culture infective dose 50% (TCID_{50%}) per dose and a 185 single IM dose of the AZ/ChAdOx-1-S vaccine at a concentration of 10¹⁰ viral 186 particles per dose for subsequent non-inferiority analysis. 187

The protocol was formulated by iLS Clinical Research, S.C. in collaboration with the 188 Mexican Institute for Social Security (IMSS) and Laboratorio Avi-Mex, S.A. de C.V. 189 190 (Avimex®), which was the sponsor. Approval for the study was granted by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) in 191 Mexico, assigned the number RNEC2022-AVXSARSCoV2VAC005, Ethics approval 192 193 was obtained from the institutional ethics committee at each research site participating in the study. The research was conducted in complete compliance with 194 Mexican regulations and in accordance with the principles outlined in the Declaration 195 of Helsinki and Good Clinical Practice. Immunological assay samples were 196 processed at the National Institute for Respiratory Diseases (INER) in Mexico City. 197

198 Study groups

The study groups comprised adults aged 18 years or older, of both genders, who
were in good health and had received at least one dose of an approved SARS-CoV2 vaccine. Inclusion criteria for the study involved a negative PCR test for SARS-

CoV-2 during the screening visit, a negative pregnancy test in women of childbearing
 potential, a commitment to maintaining adequate prevention measures to avoid
 infection with SARS-CoV-2 throughout their participation in the study, especially
 during the first 14 days after the baseline visit. Importantly, there were no restrictions
 based on the baseline antibody titers for eligibility in the study.

The exclusion criteria encompassed hypersensitivity or allergy to any ingredient of 207 208 the vaccine, a history of severe anaphylactic reactions, fever at the baseline visit, receipt of the last COVID-19 vaccination within the past 4 months, SARS-CoV-2 209 infection within the last month, pregnancy or nursing status, chronic diseases 210 requiring the use of immunosuppressive agents or immune response modulators 211 (e.g., systemic corticosteroids, cyclosporine, rituximab), active chemotherapy 212 treatment for cancer, a history of human immunodeficiency virus (HIV) infection, and 213 chronic renal or liver disease with a recent history of infectious conditions requiring 214 215 hospitalization or intravenous drug treatment within the year before the baseline visit.

The randomization of volunteers was conducted using a computer-based 216 assignment system, ensuring blinding throughout the study. Upon signing the 217 informed consent form, each participant received a patient number, encoding all their 218 information in a pseudo-anonymized manner during data collection and becoming 219 220 fully anonymized during the analysis. The stratification for subject randomization is as follows: In phase 2 and the immunobridging phase, blocks of 8 were created, with 221 each block randomly assigning 4 subjects to receive the AVX/COVID-12 vaccine 222 and 4 subjects to receive the AZ/ChAdOx-1-S vaccine. In the follow-up safety phase 223 III, blocks of 8 were also created, with all subjects receiving the AVX/COVID-12 224 225 vaccine.

In phase II, participants were enrolled to receive either the AVX/COVID-12 or
AZ/ChAdOx-1-S vaccine. During phase III immunobridging, the phase II participants
were included, and new participants were enrolled. For the phase II/III safety
assessment, volunteers from the phase III immunobridging and phase II participants
were included. Additionally, more volunteers were recruited to receive the
AVX/COVID-12 vaccine (Figure 1).

232 Safety

Safety was assessed through active and passive monitoring of adverse events (AEs)
in both the AZ/ChAdOx-1-S and AVX/COVID-12 vaccine groups, taking into account
their severity and their relationship to the intervention. The study comprised four
visits, with the option for additional visits in case of suspected SARS-CoV-2 infection.
While all participants completed the same visits, those assigned to different groups
(described above and in Figure 1) underwent additional sample collections during
visits on days 0, 14, 90, and 180 of the study.

The primary endpoints in the phase II/III and the immunobridging aspects of this trial included solicited local and systemic reactions. These reactions were assessed at the time participants entered the study and continued throughout a 6-month follow-

up period. Additionally, the study reported the incidence of symptomatic, severe, orfatal cases of COVID-19.

The classification of potential AEs and their association with vaccine exposure followed a two-period analysis. The first period included the initial 7 days following vaccination, during which adverse reactions were deemed related to the vaccine components (19). Conversely, reactions occurring after 7 days, typically in response to the development of an immune response, constituted the second analysis period

250 (19).

251 Sample collection

252 Venous blood samples were obtained from participants during scheduled site visits for serology tests and cellular response assessments. The samples were collected 253 into two sodium heparin tubes and one separator tube (SST BD vacutainer tubes, 254 Franklin Lakes, NJ, USA) through standard phlebotomy procedures. Following 255 collection, the samples were transported at room temperature to the INER for 256 257 immediate processing. All blood samples and their products were handled in a 258 biosafety level (BSL)-2 laboratory, employing appropriate personal protective 259 equipment and safety precautions, adhering to processing protocols approved by the Institutional Biosafety Committee. Serum isolation was performed by centrifuging 260 venous blood collected into SST at 2,260 x g for 10 minutes to separate the serum. 261 The resulting serum was carefully extracted from the upper portion of the tube, 262 aliquoted, and then stored at -20 °C until needed. 263

264 Peripheral blood mononuclear cell (PBMC) isolation

PBMC were isolated from venous blood collected in sodium heparin tubes (BD 265 vacutainer tubes, Franklin Lakes, NJ, USA). Within four hours of collection, PBMC 266 isolation was conducted by density-gradient sedimentation of whole blood diluted at 267 268 a 1:2 ratio in Roswell Park Memorial Institute (RPMI) 1640 medium (Lonza, Basel, Switzerland) at room temperature. The diluted blood was layered over an 269 appropriate volume of room-temperature Lymphoprep (Axis-Shield Diagnostics, 270 Dundee, UK). Then, the PBMC were then recovered, cryopreserved in a medium 271 consisting of 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO, USA) 272 and 90% heat-inactivated fetal bovine serum (FBS; GIBCO, California, USA), and 273 274 stored at -80 °C until use. For T cell assays, the thawing process involved warming 275 frozen cryovials at 37 °C in a water bath, and cells were resuspended in 5 mL of CTS OpTmizer (GIBCO, California, USA). After a wash with OpTmizer, cells were 276 counted using a Neubauer chamber, and the viability was assessed by trypan blue. 277 Cells were resuspended in OpTmizer medium to a density of 4 x 10⁶ cells/mL. 278

The subunit 1 of the spike protein of SARS-CoV-2 (RayBiotech, Peachtree Corners, GA, USA) was selected as the primary antigen due to its display of most immunogenic epitopes of the spike protein. Additionally, it contains the receptor

binding domain (RBD) fragment of the virus, which mediates binding to the hostreceptor angiotensin-converting enzyme 2 (ACE2).

284 **Pseudovirus neutralization assay**

The pseudovirus neutralization assay employed pseudovirus particles based on replication-competent vesicular stomatitis virus (VSV)-eGFP-SARS-CoV-2. These particles encoded the spike gene of the ancestral Wuhan-1 strain, as well as Omicron subvariants BA.2 (VSV-SARS-CoV-2 BA.2 clone 1) and BA.5 (VSV-SARS-CoV-2 BA.5 clone 4). The pseudovirus particles were generously provided by Sean Whelan and used in pseudoviral microneutralization assays.

Prior to use in the neutralization assay, all sera were heat-inactivated at 56 °C for 30 minutes. Vero E6 cells (ATCC CRL-1586, Manassas, VA, USA) were seeded at a density of 1.3 x 10⁴ cells per well in 96-well plates with 100 μ L of complete EMEM (Eagle's minimum essential medium, ATCC, 30-2003 Manassas, VA, USA) supplemented with 10% fetal bovine serum; (FBS; Gibco, Waltham, MA, USA). The cells were then incubated for 24 hours at 37 °C with 5% CO₂, allowing them to reach approximately 85% confluence.

The next day, serum samples were diluted in EMEM medium without FBS using a 3-fold serial dilution, starting with a 1:60 dilution. These diluted samples were mixed with 100 TCID₅₀ of VSV-SARS-CoV-2 spike pseudoparticles of the ancestral Wuhan-1 strain or Omicron variants. The mixture was incubated for 60 minutes at 37 °C with 5% CO₂ to facilitate the neutralization process. Subsequently, each dilution was transferred to a parallel plate containing Vero E6 monolayers and incubated at 37 °C with 5% CO₂ for 72 hours.

After the incubation period, 3.7% formaldehyde was added to the culture plates and 305 the plates were incubated 30-40 minutes at room-temperature. Then, the 306 formaldehyde was discarded, and the plates were washed twice with phosphate-307 308 buffered saline (PBS; Lonza, Basel, Switzerland). The neutralizing activity of each sample was reported as the titer, represented by the reciprocal of dilution, where the 309 cell protection is 50%; to get this value, we considered the last serum dilution at 310 which the wells are non-infected and with this data, the half maximal 50% inhibitory 311 dilution (ID₅₀) was calculated using the Spearman-Kaerber analysis method. This 312 analysis was based on the presence or absence of cellular damage (cytopathic 313 effect). Each sample was tested in duplicate. 314

315 Intracellular cytokine staining assay

Cells were costimulated for 16 hours with costimulation anti-human CD28/CD49d
(BD Biosciences, San Jose, CA, USA), spike subunit 1 protein at a concentration of
5 µg/mL. Medium served as a negative control, and phytohemagglutinin (PHA; 1
mg/mL) as a positive control. Monensin (GolgiStop BD, San José, CA, USA) was
added, and the samples were incubated for 4 hours at 37 °C.

After stimulation, the samples were washed with PBS (Lonza, Walkersville, MD, 321 322 USA) and stained with Live/Dead Fixable near 633 or 635nm (Invitrogen, Waltham, MA. USA) (diluted 1:1000) for 15 minutes at room temperature in the dark. 323 Subsequently, cell surface staining was performed using a cocktail of anti-human 324 CD3-Alexa Fluor 700 (Biolegend, San Diego, CA, USA), CD4-PerCP/Cy5.5 325 (Biolegend, San Diego, CA, USA), and CD8-PE/Cy7 (Biolegend, San Diego, CA, 326 USA) antibodies in cell staining buffer (BioLegend, San Diego, CA, USA). The 327 mixture was incubated for 15 minutes at room temperature in the dark, followed by 328 an additional washing step with cell staining buffer. 329

The cells were fixed and permeabilized using Cytofix/Cytoperm (BD, San Jose, USA) 330 for 20 minutes at room-temperature. After centrifugation, Perm/Wash (BD, New 331 Jersey, USA) was added. Then, intracellular staining was then performed using a 332 cocktail of anti-human IFN-y-FITC (BD, San Jose, USA), TNF-α APC (Biolegend, 333 334 San Diego, CA, USA), and IL-2-BV605 (Biolegend, San Diego, CA, USA) antibodies in Perm/Wash solution for 30 minutes at room temperature in the dark. After washing 335 with BD Perm/Wash buffer (BD, San Jose, USA), the cells were resuspended in PBS 336 and kept at 4 °C in the dark until acquisition and analysis. Unstained and 337 fluorescence minus one (FMO) controls were included. 338

339 Sample acquisition was carried out on a BD Symphony A1 instrument, previously calibrated with standardized Cytometer Setup and Tracking (CST) beads (BD, San 340 Jose, USA) used for daily guality control. Compensation was performed using 341 CompBeads (BD, San Jose, USA). At least 200,000 events of the lymphocyte region 342 in a Forward Scatter (FSC) vs Side Scatter (SSC) plot were acquired per sample. 343 Analysis was conducted using FACSDiva 8.0.3, and gates for identification of SARS-344 CoV-2 antigen-specific cytokine-producing CD3+, CD4+, or CD8+ T cells were 345 defined using the FMO controls. This study was approved by the Institutional Review 346 347 Board for Human Subjects Research at INER.

348 Statistical analysis

We present results encompassing safety, immunogenicity, efficacy, and a sample size determined through statistical hypothesis testing. To outline the study population demographic characteristics, measures of central tendency and dispersion were employed for continuous variables, while proportions were utilized for discrete or categorical variables. Continuous variables underwent analysis using the student's t-test or non-parametric test where specified, and the categorical variables were compared through a chi-square test.

Safety analysis involved the AEs comparison in participants vaccinated with AZ/ChAdOx-1-S (control group) and AVX/COVID-12 (experimental group), considering both severity and their relationship to the intervention. The Z-test was employed to compare the proportions of reported adverse effects between treatment groups. Variations in the neutralizing antibody titers and secreted IFN- γ levels were determined. Statistically significant differences in intra-groups in geometric mean neutralization titers between day 0 and day 14, 90, and 180 were analyzed using a paired t-test for the variable on a logarithmic scale, and the differences in IFN- γ production were determined using Wilcoxon signed ranks test. Significance was set at p-values < 0.05. The confidence interval for the non-inferiority criteria was obtained through a student's t-test for the variable on a logarithmic scale.

The analysis of the incidence of symptomatic, severe, or fatal cases of COVID-19 is described by Nelson Alen's cumulative hazard rate, and the difference between groups was evaluated with a log rank test.

The statistical analysis was performed with STATA v 17.0 (StataCorp, College Station, TX, USA).

373 Results

Randomization of study participants

From November 9, 2022, to September 11, 2023, a total of 4,201 volunteers 375 376 underwent eligibility assessments, and 134 subjects were excluded due to failure to 377 meet eligibility criteria. The distribution of recruited volunteers is depicted in Figure 378 1. Various research sites across different states of Mexico participated in volunteer recruitment, including Aguascalientes (Hospital Cardiológica Aguascalientes), 379 Guerrero (CICPA Centro de Investigación Clínica del Pacífico), Mexico City 380 (CAIMED Investigación en Salud, S.A. de C.V., Centro de Investigación Clínica 381 Chapultepec, CICA Centro de Investigación Clínica Acelerada, S.C., INCMNSZ 382 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Unidad de 383 Medicina Familiar No. 20 IMSS), Michoacán (Sociedad Administradora de Servicios 384 de Salud, S.C.), Oaxaca (OSMO Oaxaca Site Management Organization S.C.), 385 Quintana Roo (Red OSMO Centro de Investigación y Avances Médicos 386 387 Especializados), State of Mexico (CRI Clinical Research Institute S.C.), Veracruz (Instituto Veracruzano de Investigación Clínica S.C.), and Yucatán (Centro 388 Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en 389 Yucatán (CEMDEICY) S.C.P., K&M Köhler & Milstein Facultad de Medicina, 390 Universidad Autónoma de Yucatán, Mérida, Unidad de Atención Médica e 391 Investigación en Salud (UNAMIS)). 392

A total of 4,067 participants were initially randomized for the study, with 11 393 withdrawing consent post-randomization, and 4,056 were vaccinated. In phase II, 394 395 422 participants were enrolled, with 218 receiving the AVX/COVID-12 vaccine and 204 administered the AZ/ChAdOx-1-S vaccine. In phase III immunobridging, 1,417 396 participants were enrolled, including 705 who received the AVX/COVID-12 vaccine 397 and 712 who received the AZ/ChAdOx-1-S vaccine. For phase II, 44 AVX/COVID-398 399 12 and 36 AZ/ChAdOx-1-S vaccinees dropped out, leaving 174 AVX/COVID-12 and 168 AZ/ChAdOx-1-S participants who completed the study. In phase III 400

immunobridging, 143 AVX/COVID-12 and 127 AZ/ChAdOx-1-S vaccinees dropped
out, leaving 562 AVX/COVID-12 and 585 AZ/ChAdOx-1-S participants who
completed the study. For phase II/III safety, 4,056 participants were enrolled, 3,120
received AVX/COVID-12. In addition, 936 volunteers were vaccinated with
AZ/ChAdOx-1-S. 225 dropouts were recorded from the AVX/COVID-12 group and
127 from the AZ/ChAdOx-1-S group (Figure 1).

For the groups vaccinated with AVX/COVID-12 and AZ/ChAdOx-1-S, the average age was 39 years. No statistically significant differences were observed between the groups in terms of age, sex, race, or comorbidities, suggesting that both groups are comparable concerning these variables (Table 1).

Information regarding prior SARS-CoV-2 infection and vaccination history was collected from participants in the immunobridging study (Table 2). Results show no statistically significant difference in the average time since the last infection and that the proportion of subjects with a history of SARS-CoV-2 infection is the same for both groups. Similarly, the proportion of subjects vaccinated with different vaccine technologies is comparable, considering the number of doses received.

417 Safety after boosting with AVX/COVID-12

418 Out of the total population evaluated for safety (n=4,056 subjects), 2,111 vaccinated subjects reported adverse events during the study. Among them, 51.37% of the 419 subjects in the AVX/COVID-12 group (n=1.603) and 54.27% in the AZ/ChAdOx-1-S 420 group (n=508) experienced adverse events, showing no statistically significant 421 422 differences among the groups (Figure 2A). When categorizing events by severity (mild, moderate, or severe), it was observed that for mild events, a higher proportion 423 of subjects were affected in the AZ/ChAdOx-1-S group compared to the 424 AVX/COVID-12 vaccine group (p=0.02). Conversely, for moderate adverse events, 425 the proportion was higher in individuals who received the AVX/COVID-12 vaccine 426 (p=0.01). Finally, for severe adverse events, no statistically significant differences 427 were observed between the two groups (Figure 2A). 428

In the context of local adverse events of special interest, 800 volunteers (25.64%) 429 were documented in the AVX/COVID-12 vaccinated group, while 193 volunteers 430 (20.61%) were recorded in the AZ/ChAdOx-1-S vaccinated group. This indicates a 431 statistically significant difference (p=0.002), with a higher incidence observed in the 432 AVX/COVID-12 group compared to the AZ/ChAdOx-1-S group. Regarding 433 434 musculoskeletal and connective tissue disorders, nervous system disorders, and skin and subcutaneous tissue disorders, there were no statistically significant 435 differences observed between the two groups (Figure 2B). The analyzed disorders 436 include musculoskeletal and connective tissue issues (arthralgia, myalgia, back 437 pain, pain in a limb, and limb discomfort), local general disorders (heat, pain, edema, 438 redness, hematoma, swelling, induration, inflammation, nerve injury, itching at the 439 injection site) nervous system disorders (paresthesia) and skin and subcutaneous 440 441 tissue disorders (erythema, papule, and itching) (Table 1S).

For systemic AEs of special interest within 7 days post-vaccination, statistically 442 443 significant differences were observed only in cases of mild severity. Specifically, 496 cases (15.89%) were reported in volunteers from the AVX/COVID-12 group, 444 compared to 183 cases (19.55%) from the AZ/ChAdOx-1-S group (p=0.008) (Table 445 S2). Importantly, there was a statistically significant difference in general disorders 446 and administration site alterations in favor of the AVX/COVID-12 group (p=0.0008) 447 (Figure 2C). The analyzed disorders include vascular (flushing, hypertensive crisis, 448 and hypotension), respiratory, thoracic, and mediastinal (asthma, nasal congestion, 449 450 dyspnea, pharyngolaryngeal pain, hiccups, allergic rhinitis, rhinorrhea, cough, and productive cough), and psychiatric (mood changes, confusional state, insomnia, and 451 irritability), ocular (allergic conjunctivitis and photopsia), musculoskeletal and 452 connective tissue (arthralgia, back pain, myalgia, ligament sprain, muscle spasms, 453 and discomfort in limbs), systemic general disorders, and administration site 454 alterations (asthenia, chest pain, influenza-like illness, shivering, fatigue, peripheral 455 coldness, hyperthermia, inflammation, discomfort, general discomfort, chest 456 tightness, pyrexia, decreased thirst, and feeling cold), gastrointestinal (diarrhea, 457 abdominal distension, abdominal pain, upper abdominal pain, constipation, nausea, 458 odynophagia, vomiting, and aphthous ulcer), and nervous system (headache, 459 dizziness, migraine, paresthesia, drowsiness, and tremor), immune system 460 (hypersensitivity), ear and labyrinth (vertigo), metabolism and nutrition (decreased 461 appetite), reproductive and breast (polymenorrhea, heavy menstrual bleeding, and 462 menstrual disorders), skin and subcutaneous tissue (rash, excessive sweating, skin 463 lesions, and hives), cardiac (chest pain, palpitations, and tachycardia), and 464 infections (oral herpes) (Table 2S). 465

Regarding participants who experienced AEs potentially associated with the 466 vaccine, a total of 539 volunteers (17.27%) from AVX/COVID-12 and 122 from 467 AZ/ChAdOx-1-S (13.03%) were reported. Significant differences (p=0.01) were 468 observed in general disorders and administration site alterations (asthenia, pain at 469 470 the injection site, edema at the injection site, erythema at the injection site, chill, 471 fatigue, hematoma at the injection site, swelling, induration at the injection site, 472 inflammation at the injection site, nerve injury at the injection site, discomfort, general 473 discomfort, fever, and decreased thirst), predominantly occurring in volunteers vaccinated with AVX/COVID-12 (Figure 2D). No statistical differences were 474 observed in the other analyzed disorders (Figure 2D). 475

476 AVX/COVID-12 booster-induced neutralizing antibody titers against Wuhan-1 477 strain and Omicron SARS-CoV-2 variants of concern

The evaluation of neutralizing antibody titers in sera from AVX/COVID-12 boosted volunteers against the spike protein was conducted using the pseudovirus neutralization assay at 0, 14, 90, and 180 days post-immunization. Following the booster with AVX/COVID-12, anti-SARS-CoV-2 antibody titers against the ancestral Wuhan-1 strain or Omicron (BA.2 and BA.5) variants of concern were induced. Specifically, titers against the ancestral Wuhan-1 variant significantly increased at day 14 and slightly declined at day 90 and 180 post-immunization. In contrast, for
the BA.2 and BA.5 variants, significantly higher neutralizing titers were observed at
days 14, 90, and 180 after boosting (Figure 3A).

The pattern of neutralizing titers remained consistent for BA.2 and BA.5 variants, depicting an increase at days 14 and 90, followed by a decline at day 180 postboosting (Figure 3A). Notably, neutralizing antibody titers against the BA.2 and BA.5 variants were 1 to 3 times lower than those observed against the ancestral Wuhan-1 strain. Despite the decrease in titers at day 180, it is important to highlight that these titers against the BA.2 and BA.5 variants remained significantly higher compared to baseline levels before boosting with the AVX/COVID-12 vaccine.

As part of exploratory objectives, the magnitude of the increase in neutralizing titers 494 495 at 0, 14, 90, and 180 days, following the administration of the AVX/COVID-12 vaccine in a single IM booster dose regimen, was analyzed. This analysis was 496 stratified based on the immunization/infection history at the time of recruitment 497 (Figure 3B). The data consistently demonstrate significantly increased titers at day 498 14 across all subgroups. However, following this time point, titers tended to decrease 499 in all four subgroups. Based on this analysis, no differences were noted among the 500 subgroups following the administration of the AVX/COVID-12 vaccine booster 501 502 (Figure 3B). Here, "homologous boost" indicates using the same vaccine platform as the primary series, whereas "heterologous boost" refers to employing a different 503 vaccine platform for the primary series. Analysis of the groups was conducted 504 irrespective of their prior infection status (Figure 3B) 505

506 The neutralizing antibody titers following AVX/COVID-12 and AZ/ChAdOx-1-S 507 boosting were evaluated across participants with comorbidities and different age 508 groups. The antibody titers at day 0 and day 14 indicated that both vaccines induced 509 similar enhancements in neutralizing antibody titers among participants with 510 comorbidities and those aged > 65 and < 65 years (Figure 2S).

511 Phase III immunobridging

Similar neutralizing antibody responses after booster doses of AVX/COVID-12 or AZ/ChAdOx-1-S vaccines

The non-inferiority of AVX/COVID-12, in comparison to the AZ/ChAdOx-1-S vaccine, 514 was evaluated in 705 volunteers who received the AVX/COVID-12 booster and 712 515 who received the AZ/ChAdOx-1-S booster. Both groups were comparable, showing 516 no statistical differences in age, gender, or race. However, there were statistically 517 significant differences observed in individuals with obesity and normal body mass 518 519 index (BMI), as well as those with 0 or 1 comorbidities. Nevertheless, no differences were noted among underweight and overweight volunteers or individuals with 1, 2, 520 and 3 or more comorbidities (Table 3). Additionally, there were no statistically 521 522 significant differences in volunteers based on their prior infection or vaccination 523 history (Table 4).

524 The assessment of the non-inferiority of the AVX/COVID-12 vaccine, compared to 525 the AZ/ChAdOx-1-S vaccine, was conducted by calculating the confidence interval 526 for the ratio of geometric means of neutralizing titers and the confidence interval for 527 the difference in the proportion of subjects with seroconversion, following the WHO 528 guidelines for non-inferiority vaccine studies (19).

The analysis of the anti-Wuhan-1 strain neutralizing titers revealed well-balanced 529 530 baseline values for the overall subject sample (p=0.23) (Table 5). The geometric mean ratio between those immunized with the AVX/COVID-12 vaccine and those 531 with the AZ/ChAdOx-1-S vaccine at 14 days is 0.96, with a confidence interval of 532 533 0.85-1.06 (Table 5), demonstrating that AVX/COVID-12 is non-inferior to AZ/ChAdOx-1-S (Figure 4A). This result aligns with the non-inferiority criterion 534 recommended by the WHO, indicating a lower limit of the confidence interval greater 535 than or equal to 0.67 (21). 536

Upon further analysis of the neutralizing response, when stratifying boosted 537 volunteers into seroconverted and non-seroconverted groups, it was found that 538 58.15% of subjects in the AVX/COVID-12 vaccinated group seroconverted, while in 539 the AZ/ChAdOx-1-S vaccinated group, the proportion was 55.75%. 540 The AVX/COVID-12 vaccinated group maintains a 2.4% advantage over the 541 AZ/ChAdOx-1-S vaccinated group, with a confidence interval (CI) of -2.7 to 7.5. This 542 outcome is consistent with the protocol non-inferiority criterion, indicating that the 543 544 difference in both percentages should not exceed -10 (21). Notably, individuals in both vaccine groups who experienced seroconversion exhibited an approximately 545 546 fourfold increase in their neutralizing titers 14 days after immunization. Conversely, 547 the group that did not undergo seroconversion showed a decline in neutralizing titers 548 at day 14 after boost for both vaccines (Figure 4B). This group was characterized by 549 individuals with high titers of neutralzing antibodies prior to the vaccination boost. and these titers still remained high after the observed decline and day 14 after the 550 boost (Figure 4B) 551

552 **T-cell responses among participants immunized with AVX/COVID-12 or** 553 **AZ/ChAdOx-1-S vaccines.**

The production of IFN-γ by peripheral blood total, CD4+, and CD8+ T cells in response to stimulation with the subunit 1 of the spike protein of SARS-CoV-2 was assessed on days 0, 14, 90, and 180 in PBMCs from volunteers who received booster doses of AVX/COVID-12 (Figure 5A) or AZ/ChAdOx-1-S (Figure 5B), using flow cytometry.

In subjects vaccinated with AVX/COVID-12, a slight increase in total T cells and CD4+ T cells producing IFN- γ was observed on day 14; however, this rise did not reach statistical significance. Nevertheless, a notable increase in the percentage of IFN- γ -producing CD8+ T cells (p=0.006) was detected on day 14 compared to the baseline levels on day 0 (Figure 5A and Table 3S). Statistically significant decreases were observed in total IFN- γ -producing T cells only at day 180. In the case of the IFN- γ -producing CD4+ T cells, a decrease was noted at day 90 with no further decrease. For IFN- γ -producing CD8+ T cells, the reduction was observed only at day 180 (Figure 5A and Table 3S).

For volunteers immunized with AZ/ChAdOx-1-S, no significant increases were noted 568 in total CD4+ and CD8+ IFN-y-producing T cells (Figure 5B and Table 3S). 569 Statistically significant decreases in IFN-y-producing T cells were observed only at 570 days 90 and 180. In the case of the IFN-y-producing CD4+ T cells, the decrease 571 occurred at day 14, with no further drop observed. Finally, a reduction in IFN-y-572 producing CD8+ T cells was observed at day 90, with no subsequent change (Figure 573 574 5B and Table 3S). In Figure 5, statistically significant increases are depicted in black, and decreases are shown in red. 575

576 Similar incidence of COVID-19 cases in volunteers boosted with AVX/COVID-577 12 or AZ/ChAdOx-1-S vaccines

As part of the secondary objectives for phase III, the occurrence of symptomatic 578 579 COVID-19 cases was documented for both the AVX/COVID-12 and AZ/ChAdOx-1-S groups of boosted volunteers during the 14 days following administration. A total 580 of 37 COVID-19 cases (5.5%) were recorded in the AVX/COVID-12 boosted group. 581 582 and 42 cases were reported in the AZ/ChAdOx-1-S group (6.3%), resulting in an incidence rate per 1000 days of 0.29 and 0.32 for AVX/COVID-12 and AZ/ChAdOx-583 1-S, respectively (Table 6). Despite the trial not being designed for efficacy analysis, 584 the log rank test indicated no significant difference in the cumulative incidence of 585 COVID-19 cases between both groups (p=0.42) (Table 6). Additionally, a 586 587 comparison of Nelson-Aalen cumulative hazard incidence curves for COVID-19 588 cases reported during the 180 days after boosting with AVX/COVID-12 or 589 AZ/ChAdOx-1-S showed no statistically significant differences between volunteers vaccinated with AVX/COVID-12 or AZ/ChAdOx-1-S (Figure 6). 590

591 Discussion

592 The naturally attenuated lentogenic NDV LaSota strain is an avian virus that exhibits host-range restriction, thereby preventing productive multicycle infection in non-593 594 avian species, including humans. As a live vaccine vector, it has been employed in 595 the veterinary industry for over 70 years, demonstrating a commendable track record of safety and efficacy (22). NDV-vectored vaccines have undergone preclinical 596 studies against various coronaviruses, revealing their safety and immunogenicity in 597 natural poultry host and non-natural mammalian challenge models (23-25). The 598 natural attenuation of NDV confers an advantage over other live viral vaccines used 599 in humans, as it is unlikely to induce disease in humans or any wild or domestic avian 600 species. Studies have indicated that the introduction of foreign genes into NDV 601 genomes results in reduced pathogenicity in birds, rather than an increase (26). 602 Consequently, the NDV-based AVX/COVID-12 does not pose any discernible 603

604 environmental or agricultural risks (27). Of note, the inserted HexaPro spike protein 605 is non-functional since its fusion machinery has been disabled by the introduction of 606 the prolines and by removing the cleavage site between spike subunit 1 and spike 607 subunit 2.

The safety of the AVX/COVID-12 vaccine, administered via IM or IN routes, was 608 initially confirmed through preclinical tests conducted in pigs (10). This confirmation 609 was validated in a phase I clinical trial involving volunteers with no prior history of 610 infection or vaccination (28). Considering that a significant portion of the population 611 had previously encountered infection or received vaccination at the time of the study, 612 a subsequent phase II clinical trial was conducted to assess the safety and 613 immunogenicity of the AVX/COVID-12 vaccine as a heterologous booster dose 614 through both IM and IN routes. The trial demonstrated that the vaccine retained its 615 safety and immunogenicity when employed as a booster dose (16). Reports from 616 clinical trials involving COVID-19 NDV-based vaccines similar to AVX/COVID-12 617 also indicate that these vaccines are safe and well tolerated in humans (12-15). 618

In this study, we further analyzed the safety and immunogenicity of the AVX/COVID-12 vaccine as an IM booster in healthy adult volunteers who have gone more than four months since their last COVID-19 vaccination and/or SARS-CoV-2 infection. Additionally, a non-inferiority study was conducted using the AZ/ChAdOx-1-S vaccine as an active control. The safety, immunogenicity, and efficacy of the intranasal administration of the AVX/COVID-12 vaccine will be investigated in future studies.

The assessment of AEs and their potential association with vaccination was 626 627 conducted in 4,056 subjects over a six-month period. Of these, 3,120 received a single IM dose of the AVX/COVID-12 vaccine, while 936 received the AZ/ChAdOx-628 1-S vaccine as an active control. While the use of a placebo during the phase II 629 stages facilitates a clear definition of the immune response magnitude in subjects 630 receiving the experimental vaccine, incorporating placebo controls in pharmaceutical 631 development protocols for COVID-19 vaccines, at the time of this trial, presented an 632 ethical conflict as vaccines with emergency authorization and national vaccination 633 plans became available. Consequently, placebo controls were not employed in this 634 study. Instead, AZ/ChAdOx-1-S as active control was utilized during phase II to 635 prevent bias in subject distribution and serve as a comparator for assessing the 636 vaccine's safety. On the other hand, during the phase III stage, the active control 637 was employed to accurately define biologically relevant non-inferiority and avoid a 638 potential bio-creep effect (29). 639

The primary vaccine-associated AEs in the phase II-III study were predominantly mild and associated with the administration site. Few severe AEs were reported, no statistically significant differences were observed between the two groups, and they were not related to vaccination. However, regarding the statistically significant differences, it was found that general reactions and pain at the injection site were

more frequent in the AVX/COVID-12 group than in the AZ/ChAdOx-1-S group. 645 646 Nevertheless, systemic events were more frequent in the case of the AZ/ChAdOx-1-S group. It is important to emphasize that there were no statistical differences in 647 adverse events between the entire population vaccinated with AZ/ChAdOx-1-S or 648 AVX/COVID-12 (Figure 2A). Furthermore, the nature, incidence, and severity of 649 adverse events recorded during this study do not indicate any alarming signals 650 following the administration of the AVX/COVID-12 vaccine. The demonstrated safety 651 of the AVX/COVID-12 vaccine aligns with the outcomes of earlier clinical phases 652 (11, 16).653

654 The findings outlined in this report highlight the immunogenicity of the vaccine, evidenced by an increase in neutralizing antibody titers, not only against the 655 ancestral Wuhan-1 strain but also against the Omicron BA.2 and BA.5 variants of 656 concern (Figure 3). While the neutralizing antibody responses showed an initial 657 658 increase at day 14 followed by a gradual decline, it is noteworthy that even after 6 months, antibody titers remained higher compared to pre-boosting levels (Figure 3). 659 This persistence aligns with observations reported for other COVID-19 vaccines 660 (30). 661

Furthermore, the analysis of the geometric mean ratio (GMT) of neutralizing
antibodies demonstrated that the AVX/COVID-12 experimental vaccine (GMT ratio:
0.96, CI: 0.85-1.06) met the standard set by the WHO (GMT≥0.67) (Table 5) (21),
confirming its non-inferiority when compared to the AZ/ChAdOx-1-S vaccine.

The efficacy of the AZ/ChAdOx-1-S vaccine had been previously established in 666 clinical studies with placebo controls (31). Moreover, primary-series AZ/ChAdOx-1-667 S vaccination protects against COVID-19 hospitalization with enduring levels of 668 vaccine effectiveness through ≥6 months, as indicated by consistent results in a 669 meta-regression analysis. The analysis showed ≥80% protection against COVID-19 670 hospitalization through approximately 43 weeks post-second dose, with a certain 671 decline (17,18). This vaccine was the most widely used in vaccination campaigns in 672 Mexico and is the most utilized globally, distributed in 185 countries (2,17). 673 Therefore, it serves as an excellent active control for the non-inferiority study of the 674 AVX/COVID-12 vaccine. 675

Further data analysis indicates that a percentage of individuals in both groups did 676 not seroconvert. Approximately 40% of those vaccinated with both AVX/COVID-12 677 and AZ/ChadOx-1-S did not seroconvert when measuring response against the 678 679 ancestral Wuhan-1 strain, while it was 20% when considering those who did not seroconvert in response to Wuhan, BA.2, and BA.5 (triple negatives). In other words, 680 60% seroconverted when measuring the response against the Wuhan-1 strain, and 681 around 80% seroconverted when considering the response measured against 682 Wuhan-1 or the BA.2 or BA.5 Omicron strains. This trend was observed in both the 683 AVX/COVID-12 and AZ/ChadOx-1-S vaccinated groups (Figure 4B). 684

The lack of seroconversion has been reported both in some infected patients (32) 685 686 and vaccinated individuals (33), particularly in patients with prior infection, where seroconversion after receiving a vaccine booster is much lower or non-existent when 687 neutralizing titers are high due to previous infections (33). In this study, 32% of the 688 volunteers exhibited anti-N titers (data not shown), indicating prior infection (or 689 vaccination with inactivated vaccines). Additionally, the study was conducted during 690 a pandemic peak caused by the Omicron variant (Figure 1S), leading to around 40% 691 of participants having titers of 1,024 and above at baseline (Figure 4B). The analysis, 692 693 comparing baseline titers and the percentage of seroconversion, clearly shows that 694 higher baseline titers are associated with lower seroconversion, aligning with existing literature (33). 695

In the case of volunteers who did not seroconvert in both the AVX/COVID-12 and 696 AZ/ChadOx-1-S boosted groups, it was interestingly observed that the antibody titers 697 698 were declining at day 14 (Figure 4B). Further analysis revealed that these volunteers had very high baseline titers. This phenomenon has been previously reported in 699 similar cases (33,34), especially in volunteers with high baseline titers receiving 700 homologous boosters. Additionally, studies in mice have shown that immunization 701 schemes involving multiple doses lead to a reduced response of neutralizing 702 antibodies, with a diminished T-cell response, decreased formation of germinal 703 centers, and cellular response exhaustion (35). This information could contribute to 704 explaining the observed response in the study patients. It is also crucial to consider 705 that most of these volunteers had already developed robust hybrid immunity due to 706 previous vaccinations and infections. Furthermore, the study was conducted during 707 a peak of Omicron infections (Figure 1S), and undetected exposure to the virus could 708 have contributed to the observed response. These data indicate that in individuals 709 with high neutralizing antibody titers, the boosting does not improve the response: 710 on the contrary, it could not prevent waning in antibody titers. This information is 711 relevant for planning and deploying vaccination campaigns to maximize the benefits 712 713 of vaccination.

Nevertheless, the analysis of the volunteers' neutralizing antibody responses 714 confirmed that the AVX/COVID-12 vaccine meets the WHO non-inferiority standard 715 716 compared to the AZ/ChAdOx-1-S vaccine. Individuals with baseline neutralization titers around 400, boosted either with AVX/COVID-12 or AZ/ChAdOx-1-S, exhibited 717 718 a 3 to 4-fold increase in seroconversion for both groups (Figure 4A and 4B). These 719 results underscore the effectiveness and importance of timely boosting in specific 720 individuals. It is important to note that this trial included participants regardless of their initial anti-S IgG titers. The seroconversion observed in volunteers with initially 721 722 low antibody titers aligns with phase II clinical trial findings, where participants had 723 similarly low anti-S IgG titers at the beginning of the study (16). Notably, this phase 724 II/III study demonstrates that boosting individuals with high neutralizing antibody 725 titers does not result in a further increase; in fact, it might not stop antibody waning, though this decline does not reach initial levels as high antibody titers persist. 726

The primary focus of anti-COVID-19 boosting campaigns is on the elderly, 727 728 immunocompromised, and individuals with comorbidities. Upon further examination of neutralizing antibody titers following AVX/COVID-12 or AZ/ChAdOx-1-S boosting, 729 both vaccines exhibited comparable enhancements in neutralizing antibody titers 730 among participants with comorbidities, as well as those aged > 65 and < 65 years 731 (Figure 2S). This data supports the use of these vaccines as boosters in these 732 populations. Further studies are required to evaluate the safety and immunogenicity 733 of this vaccine in immunocompromised indviduals, pregnant women and kids. 734

With time, the combination of infection and vaccination generates hybrid immunity. 735 which has been demonstrated to broaden and enhance the neutralizing antibody 736 T-cell responses. providing increased protection against infection, 737 and hospitalization, and death (36). This report illustrates the induction of a neutralizing 738 response against the Omicron variant of concern (VOC) through boosting with 739 740 AVX/COVID-12 or AZ/ChAdOx-1-S. Since both vaccines express the spike protein of the ancestral Wuhan-1 strain, the anti-Omicron neutralizing response may be 741 attributed to extensively documented cross-reactivity. This phenomenon is 742 particularly evident in the context of hybrid immunity, which has been shown to 743 broaden and enhance the response of neutralizing antibodies, not only against the 744 ancestral variant but also against new variants and other seasonal coronaviruses as 745 well as SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS 746 CoV) (33). Given the pandemic status when the trial was conducted, the induction 747 of antibodies against variants other than Wuhan-1 is not surprising, considering the 748 large number of T and B cell epitopes shared by the spike proteins from SARS-CoV-749 2 variants of concern (37). 750

Regarding the cellular response, an increase in the total CD4+ and CD8+ T cell 751 responses was observed on day 14 after receiving the booster dose. However, the 752 increase was statistically significant only for CD8+ cells producing IFN- γ . It is 753 754 important to note that the data suggest that at the initiation of this study, the proportions of IFN-γ-producing T lymphocytes were relatively high in the participating 755 subjects, as there is a trend indicating a significant decrease at days 90 and 180. 756 This trend is also observed for subjects enrolled in the group that received the 757 AZ/ChAdOx-1-S vaccine, suggesting that, at a population level, due to the active 758 circulation of the virus, there were initially high baseline levels of T lymphocytes 759 specific to the SARS-CoV-2 spike protein. While it was possible to detect significant 760 increases in the specific cellular response to the virus, the high baseline levels 761 prevented clearer observations of cellular response increases (Figure S1). 762 763 Considering the inclusion criteria, which allowed the recruitment of individuals vaccinated or previously infected with SARS-CoV-2 for four months or more, it is 764 anticipated that the cellular response would already be elevated (30). This makes it 765 challenging to observe a distinct increase after the booster. Reports from 2022 766 767 estimated that at least 51% of the population had hybrid immunity, with 85% exhibiting some level of Omicron-induced antibody titers (38). Additional studies 768

propose limited potential for further boosting, notably in individuals initially primed 769 770 with infection followed by three mRNA vaccine doses, which maximally induce spikespecific T-cell responses (39). This report also illustrates that a previous history of 771 SARS-CoV-2 infection can modify immune responses to the spike protein during 772 Omicron infection in vaccinated populations. Nevertheless, Omicron infection in 773 individuals who have received triple vaccinations generally heightens immune 774 responses to SARS-CoV-2 in both the bloodstream and mucosal regions. This 775 enhancement potentially fortifies long-lasting population immunity against SARS-776 777 CoV-2 (39). Other studies have indicated that vaccination with BNT162b2, based on the Wuhan-1 spike protein, and/or breakthrough infection by early Omicron 778 subvariants elicits CD8+ T cell responses that recognize epitopes within the spike 779 protein of newly emerging subvariants (40). 780

Collectively, these findings suggest that hybrid immunity acquired from both
 vaccination and past infections can prompt notably heightened and broader immune
 responses. This combined immunity shows the potential to offer protection against
 emerging variants of concern.

The evaluation of COVID-19 cases among recipients of AVX/COVID-12 or AZ/ChAdOx-1-S vaccines revealed no cases of severe disease, with only mild to moderate disease observed in both groups. An analysis conducted 14 days postvaccination indicated a trend towards a lower occurrence of COVID-19 cases in individuals boosted with AVX/COVID-12 in comparison to the AZ/ChAdOx-1-S vaccine group, despite the trial not being designed for efficacy analysis.

The urgent need persists for the development of safe, effective, and cost-efficient vaccines against COVID-19, especially for implementing booster campaigns aimed at vulnerable groups like the elderly, immunocompromised individuals, and those with comorbidities. This also serves the crucial goal of limiting transmission among the wider population. The results presented here collectively support the utilization of the AVX/COVID-12 vaccine to address this pressing need.

797 Conclusions

Our findings demonstrate that the AVX/COVID-12 vaccine is safe, well-tolerated, 798 and highly immunogenic. It effectively stimulated the production of neutralizing 799 antibodies against the spike protein from both the ancestral Wuhan-1 strain and the 800 Omicron variants BA.2 and BA.5. Additionally, at day 14 post-immunization, 801 802 AVX/COVID-12 uniquely induced IFN-y-producing CD8+ T cells. Furthermore, a discernible trend indicated a potentially lower incidence of COVID-19 cases among 803 volunteers who received the AVX/COVID-12 booster compared to those who 804 received the AZ/ChAdOx-1-S vaccine, supporting the conclusion of non-inferiority. 805 Consequently, the AVX/COVID-12 vaccine meets the WHO's non-inferiority 806 standard when compared to AZ/ChAdOx-1-S. These compelling findings strongly 807 advocate for the incorporation of the AVX/COVID-12 vaccine as a booster dose for 808 809 the general population.

810 Acknowledgments

From CONAHCYT, we acknowledge María Elena Álvarez-Buylla Roces and Delia 811 Aideé Orozco Hernández for their role as an inter-institutional liaison and overall 812 813 facilitation of proceedings, committee evaluations, sanitary setup, and follow-up of trial design approvals, evaluations, and progress. We additionally acknowledge the 814 broader support from various teams within all the clinical research sites and iLS 815 Clinical Research S.C., particularly Gabriela Rosas, Daniela Castro, Claudia Aguilar, 816 Roman Jarosch, and Alejandro Arias. From Laboratorio Avi-Mex, S. A. de C. V., we 817 acknowledge the following people for their operative support: Bernardo Lozano 818 819 Alcántara, Alejandro Ruiz, Rosalba Rodríguez, Leticia Espinosa Gervasio, Rodrigo Yebra Reyes, Vanessa Escamilla Jiménez, Jaime Becerra Jiménez, Lorena Juárez 820 Pedraza, Sandra Yuridia Ang Tinajero, Avelia Ariadna Cuevas Cifuentes, Juan 821 Pablo Robles Álvarez, Avirán Almazán Gutiérrez, Aurora Betsabé Gutiérrez 822 Balderas, Merlenne Rubio Díaz, and Guadalupe Aguilar Rafael. From INER, we 823 824 acknowledge the following people for their technical support: Liliana Figueroa Hernández, Francisco Cruz Flores, Claudia Ivett Hernández Lazaro, María Angelica 825 Velázguez González, Jessica Romero Rodríguez, Dulce Cinthia Soriano 826 Hernández, Milton Nieto Ponce, Edgar Reyna, Itzel Corona, José E. Marquez, 827 Angelica Moncada, and Pablo Franco-Mendoza. From IMSS, we acknowledge the 828 help of Diego Lozano-Cisneros in formatting the manuscript. From the Icahn School 829 of Medicine at Mount Sinai, we acknowledge Sean Whelan. From Instituto 830 Politécnico Nacional, Escuela Nacional de Ciencias Biológicas, we acknowledge 831 Sonia Mayra Pérez Tapia, Alexis Gabriel Suárez Gómez, and Sandra Comparan 832 Alarcón. 833

Funding: The funding for the clinical study was provided by the National Council for 834 Humanities, Science and Technology (CONAHCYT, México), except for all the 835 production and vaccine product supply, which was funded solely by Laboratorio Avi-836 Mex, S. A. de C. V. (Avimex). CONAHCYT did not participate in the trial design but 837 did evaluate it and approved the project through their National Committee for 838 Science, Technology and Innovation in Public Health. Funding was managed by 839 Avimex and used to pay for all laboratory tests, clinical sites, and clinical 840 professionals. CONAHCYT also facilitated the identification, purchase, and 841 importation of certain supplies and the communication with other entities of the 842 Federal Mexican Government to facilitate the study. 843

Conflict of Interest: The vaccine candidate administered in this study was 844 developed by faculty members at the Icahn School of Medicine at Mount Sinai 845 including P.P., F.K. and A.G.-S. Mount Sinai is seeking to commercialize this 846 vaccine; therefore, the institution and its faculty inventors could benefit financially. 847 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to 848 SARS-849 CoV-2 serological assays (USA Provisional Application Numbers: 849 850 62/994,252, 63/018,457, 63/020,503, and 63/024,436) and NDV-based SARS-CoV-851 2 vaccines (USA Provisional Application Number: 63/251,020) which list FK as co-

inventor. A.G.-S. and P.P. are a co-inventor in the NDV-based SARS-CoV-2 vaccine 852 patent application. Patent applications were submitted by the Icahn School of 853 Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market 854 serological tests for SARS-CoV-2 and another company, CastleVax, to 855 commercialize SARS-CoV-2 vaccines. F.K., P.P. and A.G.-S. serve on the scientific 856 advisory board of CastleVax and are listed as co-founders of the company. F.K. has 857 consulted for Merck, Seqirus, Curevac, and Pfizer, and is currently consulting for 858 Gritstone, Third Rock Ventures, GSK, and Avimex. The F.K. laboratory has been 859 collaborating with Pfizer on animal models of SARS-CoV-2. C.L.-M. has consulted 860 for AstraZeneca. The A.G.-S. laboratory has received research support from GSK, 861 Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, 862 Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, 863 Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied 864 Biological Laboratories and Merck. A.G.-S. has consulting agreements for the 865 following companies involving cash and/or stock: Amovir, Vivaldi Biosciences, 866 Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied 867 Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, 868 Synairgen, Paratus, Pfizer and Prosetta. A.G.-S. has been an invited speaker in 869 meeting events organized by Seqirus, Janssen, Abbott, and AstraZeneca. P.P. has 870 a consulting agreement with Avimex. 871

872 Members of Avimex developed the live vaccine used in this study. Avimex filed 873 patent applications with Mount Sinai and CONAHCYT. M.T., D.S.-M., C.L.-M., 874 H.E.C.-C., F.C.-P., G.P.D.L., and B.L.-D. are named as inventors on at least one of 875 those patent applications. The clinical study was entirely performed in Mexico and 876 Mount Sinai had no role in the clinical study. The rest of the participants are 877 employees of their corresponding institutions and declare no competing interests.

Ethical Responsibilities: The protocol was approved by the ethics, research, and
biosafety committees of each clinical research site, National Committee for Science,
Technology and Innovation in Public Health of the National Council for Humanities,
Science, and Technology (CONAHCYT), and also by the Federal Commission for
the Protection against Sanitary Risks (COFEPRIS, Mexico) as a regulatory agency.

Protection of Humans and Animals: No animals were used in this study. The
protocol was designed to comply with the ethical principles of the Helsinki
Declaration, Good Clinical Practices, and the applicable Mexican law.

Data Confidentiality and Sharing: The protocol was registered in the National Registry of Clinical Studies under number RNEC2022-AVXSARSCoV2VAC005 and published under NCT05710783. Individual de-identified participant data will not be shared beyond the limits permitted by the informed consent and Mexican law. Specifically, this includes the sharing of the study protocol, statistical analysis plan, informed consent form, and approved clinical study report. Additionally, other deidentified data allowed under the informed consent and Mexican law may be shared.

The data will be made available immediately upon publication and for 12 months 893 894 thereafter. Access to the data will be granted solely to investigators with methodologically sound proposals, subject to authorization by an independent 895 review committee and the ethics committees involved in approving the protocol. If 896 required by law, authorization from the Federal Commission for the Protection 897 against Sanitary Risks (COFEPRIS) in Mexico will also be obtained. Any use of the 898 data must strictly adhere to the authorized purposes outlined during the approval 899 process. 900

Privacy Rights and Informed Consent: Informed Consent formats were provided
and signed by all participants under Good Clinical Practices and Mexican law.
Personal data is confidential, and subjects are not identified personally. Their data
was analyzed and duly de-identified.

905 References

- WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19)
 Dashboard With Vaccination Data [Internet]. [cited 2023 Jan 5]. Available
 from: https://covid19.who.int/
- 2. Coronavirus Pandemic (COVID-19) Our World in Data [Internet]. [cited
 2023 Nov 15]. Available from: https://ourworldindata.org/coronavirus
- 911 3. COVID19 Vaccine Tracker [Internet]. [cited 2023 Nov 15]. Available from:
 912 https://covid19.trackvaccines.org/
- 913 4. Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and safety of 914 covid-19 vaccines in phase iii trials: A meta-analysis. Vaccines [Internet].
 915 2021 Jun 1 [cited 2023 Nov 15];9(6). Available from: 916 /pmc/articles/PMC8228087/
- 917 5. Global Dashboard for Vaccine Equity UNDP Data Futures Platform
 918 [Internet]. [cited 2023 Jan 5]. Available from: https://data.undp.org/vaccine919 equity/
- Seephetdee C, Buasri N, Bhukhai K, Srisanga K, Manopwisedjaroen S,
 Lertjintanakit S, et al. Mice immunized with the vaccine candidate hexapro
 spike produce neutralizing antibodies against sars-cov-2. Vaccines.
 2021;9(5):1–9.
- 924 7. Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, 925 et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes.
 926 Science [Internet]. 2020 Sep 1 [cited 2023 Nov 15];369(6510):1501–5.
 927 Available from: https://pubmed.ncbi.nlm.nih.gov/32703906/
- Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig
 S, et al. A Newcastle disease virus expressing a stabilized spike protein of
 SARS-CoV-2 induces protective immune responses. Nat Commun 2021 121
 [Internet]. 2021 Oct 27 [cited 2023 Jan 5];12(1):1–14. Available from:
 https://www.nature.com/articles/s41467-021-26499-y

- 933
 9. Park JG, Oladunni FS, Rohaim MA, Whittingham-Dowd J, Tollitt J, Hodges
 934
 MDJ, et al. Immunogenicity and protective efficacy of an intranasal live-
- 935 attenuated vaccine against SARS-CoV-2. iScience [Internet].
- 936 2021;24(9):102941. Available from:
- 937 https://doi.org/10.1016/j.isci.2021.102941
- 10. Lara-Puente JH, Carreño JM, Sun W, Suárez-Martínez A, Ramírez-Martínez
 L, Quezada-Monroy F, et al. Safety and Immunogenicity of a Newcastle
 Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID12-HEXAPRO (Patria), in Pigs. MBio [Internet]. 2021 Oct 1 [cited 2023 Jan
 5];12(5). Available from: https://pubmed.ncbi.nlm.nih.gov/34544278/
- Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty
 P, Carranza-Salazar DE, et al. Interim safety and immunogenicity results
 from an NDV-based COVID-19 vaccine phase I trial in Mexico. npj Vaccines
 [Internet]. 2023;8(1):67. Available from: https://doi.org/10.1038/s41541-02300662-6
- Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc
 Dang M, et al. Safety and immunogenicity of an egg-based inactivated
 Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim
 results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
 Vaccine [Internet]. 2022 Jun 9 [cited 2023 Nov 15];40(26):3621–32. Available
 from: https://pubmed.ncbi.nlm.nih.gov/35577631/
- Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul
 S, Sivakorn C, et al. Safety and immunogenicity of an inactivated
 recombinant Newcastle disease virus vaccine expressing SARS-CoV-2
 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.
 EClinicalMedicine [Internet]. 2022 Mar 1 [cited 2023 Nov 15];45. Available
 from: https://pubmed.ncbi.nlm.nih.gov/35284808/
- 960 14. Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul
 961 S, Sivakorn C, et al. Safety and Immunogenicity of an Inactivated
 962 Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2
 963 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2
 964 Trial. medRxiv [Internet]. 2021 Sep 22 [cited 2023 Nov
- 965 15];2021.09.17.21263758. Available from:
- 966 https://www.medrxiv.org/content/10.1101/2021.09.17.21263758v2
- 96715.องศ์การเภสัชกรรม (อภ.) the Government Pharmaceutical Organization (GPO)968Thailand [Internet]. [cited 2024 Jan 29]. Available from:969https://www.gpo.or.th/view/1029
- 970
 16. Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, Niels
 971
 972
 973
 973
 974
 974
 974
 975
 976
 976
 977
 978
 979
 979
 979
 970
 970
 970
 970
 970
 970
 971
 972
 973
 974
 974
 974
 974
 974
 974
 975
 975
 976
 976
 977
 978
 978
 979
 979
 970
 970
 970
 970
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974
 974</

975 976 977		Controlled Randomized Phase, Assessing Single-Dose Intramuscular or Intranasal Administration to Evaluate the Safety and Immunogenicity of the Recombinant Vaccine Agains. Manuscr Submitt medRxiv. 2024;
978 979 980 981	17.	Abdel-Qader DH, Abdel-Qader H, Silverthorne J, Kongkaew C, Meslamani AZA, Hayajneh W, et al. Real-World Effectiveness of Four Types of COVID- 19 Vaccines. Vaccines [Internet]. 2023 May 1 [cited 2023 Nov 15];11(5). Available from: https://pubmed.ncbi.nlm.nih.gov/37243089/
982 983 984 985 986	18.	Meeraus W, de Munter L, Gray CM, Dwivedi A, Wyndham-Thomas C, Ouwens M, et al. Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta- regression analysis. Lancet Reg Heal - Eur. 2023 Aug 1;31:100675.
987 988 989 990	19.	Covid World Vaccination Tracker - The New York Times [Internet]. [cited 2023 Nov 15]. Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
991 992 993 994	20.	COVID-19: dosis confirmadas de vacunas en México 2021 Statista [Internet]. [cited 2023 Nov 15]. Available from: https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas- covid-mexico/
995 996 997 998	21.	Guidelines on clinical evaluation of vaccines: regulatory expectations, Annex 1, TRS No 924 [Internet]. [cited 2023 Nov 15]. Available from: https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of- vaccines-regulatory-expectations
999 1000	22.	Samal SK. Newcastle disease virus. Avian Virol Res Futur Trends, 1st ed; Samal, SK, Ed. 2019;43–85.
1001 1002 1003 1004 1005	23.	DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A [Internet]. 2007 Jun 5 [cited 2023 Nov 15];104(23):9788–93. Available from: https://pubmed.ncbi.nlm.nih.gov/17535926/
1006 1007 1008 1009 1010	24.	LIU R qiang, GE J ying, WANG J ling, SHAO Y, ZHANG H lei, WANG J liang, et al. Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels. J Integr Agric JIA [Internet]. 2017 Oct 1 [cited 2023 Nov 15];16(10):2264–73. Available from: https://pubmed.ncbi.nlm.nih.gov/32288953/
1011 1012 1013 1014 1015	25.	Shirvani E, Paldurai A, Manoharan VK, Varghese BP, Samal SK. A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV. Sci Rep [Internet]. 2018 Dec 1 [cited 2023 Nov 15];8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/30097608/

Park M-S, Steel J, García-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proc Natl Acad Sci [Internet]. 2006 May 23;103(21):8203–8.
Available from: https://doi.org/10.1073/pnas.0602566103

- Shirvani E, Samal SK. Newcastle Disease Virus as a Vaccine Vector for
 SARS-CoV-2. Pathog (Basel, Switzerland) [Internet]. 2020 Aug 1 [cited 2023
 Nov 15];9(8):1–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32751194/
- Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty
 P, Carranza-Salazar DE, et al. Safety and immunogenicity of a live
 recombinant Newcastle disease virus-based COVID-19 vaccine (Patria)
 administered via the intramuscular or intranasal route: Interim results of a
 non-randomized open label phase I trial in Mexico. medRxiv [Internet]. 2022
 Feb 9 [cited 2023 Nov 15];7–127. Available from:
- 1029 /pmc/articles/PMC8845421/
- Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials.
 Stat Med [Internet]. 2010 Nov [cited 2023 Nov 15];29(27):2769–80. Available
 from: https://pubmed.ncbi.nlm.nih.gov/20809482/
- 30. Guerrera G, Picozza M, D'Orso S, Placido R, Pirronello M, Verdiani A, et al.
 BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a
 stem cell memory phenotype. Sci Immunol [Internet]. 2023 Jul
 12;6(66):eabl5344. Available from:
 https://doi.org/10.1126/sciimmunol.abl5344
- 103831.Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et1039al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
- 1040SARS-CoV-2: an interim analysis of four randomised controlled trials in1041Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
- 1042 32. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti
 1043 S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19
 1044 patients and healthy volunteers up to 6 months post disease onset. Eur J
 1045 Immunol [Internet]. 2020 Dec 1 [cited 2023 Nov 15];50(12):2025–40.
 1046 Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048970
- 1047 33. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al.
 1048 Immunogenicity of standard and extended dosing intervals of BNT162b2
 1049 mRNA vaccine. Cell [Internet]. 2021 Nov 11 [cited 2023 Nov
 1050 15];184(23):5699-5714.e11. Available from:
- 1051 https://pubmed.ncbi.nlm.nih.gov/34735795/
- 34. Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet (London, England) [Internet]. 2022 Feb 5 [cited 2023 Nov 15];399(10324):521–9. Available from:

1058 https://pubmed.ncbi.nlm.nih.gov/35074136/

- 105935.Gao FX, Wu RX, Shen MY, Huang JJ, Li TT, Hu C, et al. Extended SARS-1060CoV-2 RBD booster vaccination induces humoral and cellular immune1061tolerance in mice. iScience [Internet]. 2022 Dec 22 [cited 2023 Nov
- 1062 15];25(12):105479. Available from:
- 1063 http://www.cell.com/article/S2589004222017515/fulltext
- Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM,
 et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron
 Infections. N Engl J Med [Internet]. 2022 Jul 7 [cited 2023 Nov
 15];387(1):21–34. Available from:
- 1068 https://pubmed.ncbi.nlm.nih.gov/35704396/
- 37. Pacheco-Olvera DL, Saint Remy-Hernández S, García-Valeriano MG,
 Rivera-Hernández T, López-Macías C. Bioinformatic Analysis of B- and Tcell Epitopes from SARS-CoV-2 Structural Proteins and their Potential
 Cross-reactivity with Emerging Variants and other Human Coronaviruses.
 Arch Med Res [Internet]. 2022 Nov 1 [cited 2024 Jan 19];53(7):694–710.
 Available from: https://pubmed.ncbi.nlm.nih.gov/36336501/
- 1075 38. Frei A, Kaufmann M, Amati R, Dettwiler AB, Wyl V von, Annoni AM, et al.
 1076 Development of hybrid immunity during a period of high incidence of 1077 infections with Omicron subvariants: A prospective population based multi-1078 region cohort study. medRxiv [Internet]. 2022 Oct 17 [cited 2023 Nov 15]:2022.10.14.22281076. Available from:
- 1080 https://www.medrxiv.org/content/10.1101/2022.10.14.22281076v1
- Hornsby H, Nicols AR, Longet S, Liu C, Tomic A, Angyal A, et al. Omicron
 infection following vaccination enhances a broad spectrum of immune
 responses dependent on infection history. Nat Commun 2023 141 [Internet].
 2023 Aug 21 [cited 2023 Nov 15];14(1):1–16. Available from:
 https://www.nature.com/articles/s41467-023-40592-4
- 40. Kim SH, Kim J, Jung S, Noh JY, Kim J, Park H, et al. Omicron BA.2
 breakthrough infection elicits CD8+ T cell responses recognizing the spike of
 later Omicron subvariants. Sci Immunol. 2024;9(91):eade6132.

1089




Figure 1. Participant Screening and Randomization. A flowchart illustrating the screening, randomization, and distribution of participants among different experimental groups throughout the study.







Figure 2. Local and systemic adverse events 7 days after boosting with AVX/COVID-12 or ChAdOx-1-S. Compilation of clinical data and adverse events in participants following boosting with AVX/COVID-12 or ChAdOx-1-S vaccines. A) Percentage of participants affected by adverse events classified by severity; B) participants affected by local adverse events of special interest; C) participants affected by systemic adverse events of special interest, and D) participants affected by adverse events with a confirmed relation to the vaccine according to the investigator's criteria. The analyzed disorders are listed in suplementary tables 1 and 2. p-values were calculated through a comparison of proportions using the Z-test. Statistically significant differences were observed with p-values: $p \le 0.05$.



Days after boosting with AVX/COVID-12

Figure 3. AVX/COVID-12 boosting induced neutralizing antibody titers against ancestral Wuhan-1 and Omicron SARS-CoV-2 variants of concern. Assessment of neutralizing antibody titers in sera from AVX/COVID-12 boosted volunteers against the S protein using the pseudovirus neutralization assay. A) Anti- SARS-CoV-2 antibody titers against Wuhan-1 or Omicron (BA.2 and BA.5) variants of concern. B) Specific neutralizing antibody titers against Wuhan-1 strain in participants with different history of immunization and infection induced by AVX/COVID-12 vaccine boost. Homologous boost refers to the use of the same vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination. ± Infection groups includes infected and non-infected participants. The limit of detection is 60, although it is not specified in the graph. Dots represent the geometric mean, while bars indicate the 95% confidence intervals for the error. The p-values from the statistical analysis are presented in bold numbers, where p>0.05 is considered statistically significant. A paired t-test was employed to compare neutralizing titers.




Figure 4. Similar neutralizing antibody responses were observed in participants who received booster doses of AVX/COVID-12 or AZ/ChAdOx-1-S. Analysis of neutralizing antibody titers against Wuhan-1 strain in participants boosted with AVX/COVID-12

(red circles) or AZ/ChAdOX-1-S (gray squares): A) Antibody titers in all boosted subjects on days 0 and 14 and B) comparison between participants who seroconverted (closed symbols) and subjects who did not seroconverted (open symbols). No statistically significant differences were observed, with p>0.05 considered as the threshold for statistical significance.




Figure 5: T cell responses in participants vaccinated with AVX/COVID-12 or AZ/ChAdOx-1-S vaccines. A) Percentage of IFN- γ -producing total, CD4+ and CD8+ T cells from peripheral blood mononuclear cells collected from participants who received booster doses of AVX/COVID-12 or B) AZ/ChAdOx-1-S vaccines. The cells were stimulated with the subunit 1 of spike protein, and the production of IFN- γ was assessed using flow cytometry. The limit of detection (LoD) of the % IFN- γ producing total T cells is 0.006, % IFN- γ producing CD4+ T cells is 0.006 and % IFN- γ producing CD8+ T cells is 0.006. The graph shows individual value. Bars shows geometric Mean, and the error shows the 95% confidence intervals. Statistically significant increases are depicted in black; this was observed only in IFN- γ -producing T cells from participants vaccinated with AVX/COVID-12. Statistically significant differences with decreases are shown in red. p-values: p≤0.05 for intragroup comparisons using the Wilcoxon Friedman signed-rank test.






Figure 6. The incidence of COVID-19 cases showed no statistically significant difference between the participants vaccinated with AVX/COVID-12 or AZ/ChAdOx-1-S. Comparison of Nelson-Aalen cumulative hazard incidence curves for COVID-19 cases reported during the 180 days after boosting with AVX/COVID-12 or AZ/ChAdOx-1-S.



Supplementary Figure 1. COVID-19 incidence in Mexico during the recruitment and monitoring of the study participants.



Supplementary Figure 2. AVX/COVID-12 and AZ/ChAdOx-1-S Boosting Elicited Comparable Increases in Neutralizing Antibody Titers Among Participants with Comorbidities, as well as in Subjects >65 and <65 Years Old. The geometric mean and confidence interval for antibody titers at day 0 and day 14 are displayed for AVX/COVID-12 (red circles) and AZ/ChAdOx-1-S (gray squares). Both vaccines exhibited comparable rises in neutralizing antibody titers among participants with comorbidities and in those aged >65 and <65 years old.

Tables

Table 1. Phase II/III demographic characteristics

	AVX	AZ
n (%)	3120	936
Age, mean (SD)	39.8 (15.2)	39.6 (14.6)
Age groups		
< 20 years old	116 (3.7)	43 (4.5)
20 - 29 years old	903 (28.9)	264 (28.2)
30 - 39 years old	622 (19.9)	180 (19.2)
40 - 49 years old	612 (19.6)	189 (20.1)
50 - 59 years old	496 (15.9)	163 (17.4)
60 - 69 years old	260 (8.3)	78 (8.3)
70 - 79 years old	97 (3.1)	16 (1.7)
80 and more	14 (0.4)	3 (0.3)
Gender, n (%)		
Male	1430 (45.8)	440 (47)
Female	1690 (54.2)	496 (53)
BMI, mean (SD)	28 (5.3)	28.6 (5.5)
BMI classification		
Underweight	32 (1)	9 (1)
Normal	966 (31)	228 (24.4)
Overweight	1168 (37.4)	370 (39.5)
Obesity	954 (30.5)	329 (35)
Race, n (%)		
Amerindian	24 (0.77)	16 (1.7)
White	157 (5)	73 (7.8)
Mexican Mestizo	2928 (93.8)	836 (89.3)
Other	11 (0.35)	11 (1.1)
Comorbidities, n (%)		
0	2665 (85.4)	781 (83.4)
1	361 (11.6)	128 (13.7)
2	94 (3)	27 (2.9)
3 or more	9 (0.28)	7 (0.74)
Asthma	36 (1.15)	12 (1.3)
Systolic arterial hypertension	297 (9.5)	104 (11.1)
Type 2 Diabetes Mellitus	216 (6.9)	66 (7.1)

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation, BMI = Body Mass Index.

Table 2. History of prior SARS-CoV-2 vaccination and/or infection of the phase II/III participants at baseline

n (%)	AVX	AZ

	3120	936
Prior infection, n (%)	191 (6.1)	53 (5.6)
Time (months) since last infection, mean (SD)	14.2 (10.8)	12.2 (10.9)
Number of prior vaccines, n (%)		
1	1103 (35.35)	313 (33.44)
2	1324 (42.44)	394 (42.09)
3	600 (19.23)	211 (22.54)
4	87 (2.79)	18 (1.92)
5	6 (0.19)	0
Previous vaccination dose(s) received, n (%)		
AstraZeneca		
1	914 (29.29)	252 (26.92)
2	754 (24.17)	236 (25.21)
3 or more	146 (4.68)	53 (5.66)
Pfizer		
1	133 (4.26)	45 (4.81)
2	458 (14.68)	126 (13.46)
3	12 (0.38)	5 (0.53)
CanSino		
1	411 (13.17)	172 (18.38)
2	52 (1.67)	10 (1.07)
3	1 (.03)	0
Sputnik		
1	196 (6.28)	50 (5.34)
2	186 (5.96)	44 (4.70)
3	43 (1.38)	9 (0.96)
Sinovac		
1	81 (2.60)	28 (2.99)
2	148 (4.74)	34 (3.63)
3	3 (0.10)	0
Moderna		
1	78 (2.50)	34 (3.63)
2	38 (1.22)	9 (0.96)
3	2 (0.06)	0
Novavax		
1	7 (0.22)	5 (0.53)
2	10 (0.32)	3 (0.32)
3	35 (1.12)	22 (2.35)
Coronavac		
1	8 (0.26)	0
2	20 (0.64)	3 (0.32)
Janssen		
1	14 (0.45)	5 (0.53)

n (%)	AVX 3120	AZ 936
2	12 0.38)	5 (0.53)
Sinopharm		
1	2 (0.06)	0
Curevac		
1	0	0
2	0	2 (0.21)

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation.

	AVX	AZ	p-Value
n (%)	705 (49.7)	712 (50.3)	
Age, mean (SD)	40.3 (14.8)	40.3 (14.5)	0.81
Age groups			
< 20 years old	25 (3.5)	28 (3.9)	0.61
20 – 29 years old	195 (27.6)	191 (26.8)	
30 - 39 years old	134 (19)	135 (18.9)	
40 - 49 years old	152 (21.5)	149 (20.9)	
50 – 59 years old	111 (15.7)	137 (19.2)	
60 - 69 years old	67 (9.5)	59 (8.2)	
70 – 79 years old	18 (2.5)	11 (1.5)	
80 and more	3 (0.4)	2 (0.2)	
Gender, n (%)			
Male	330 (46.8)	341 (47.9)	0.68
Female	375 (53.2)	371 (52.1)	
BMI, mean (SD)	27.9 (5.1)	28.8 (5.5)	0.002
BMI classification			
Underweight	5 (0.7)	7 (1)	0.008
Normal	214 (30.3)	162 (22.7)	
Overweight	271 (38.4)	285 (40)	
Obesity	215 (30.5)	258 (36.2)	
Race, n (%)			
Amerindian	13 (1.8)	14 (1.9)	0.71
White	39 (5.5)	50 (7)	
Mexican Mestizo	643 (91.2)	638 (89.6)	
Other	10 (1.4)	10 (1.4)	
Comorbidities, n (%)			
0	433 (61.4)	380 (53.3)	0.01
1	216 (30.6)	249 (34.9)	
2	43 (6.1)	65 (9.13)	

3 o more	13 (1.8)	18 (2.5)	
Asthma	7 (1.0)	8 (1.1)	0.81
Systolic arterial hypertension	59 (8.3)	83 (11.6)	0.04
Type 2 Diabetes Mellitus	41 (5.8)	56 (7.8)	0.12

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation, BMI = Body Mass Index. Mann–Whitney U tests were conducted for the comparison for continuous variables, and the Chi-Square test for categorical variables. In instances where a p-value is not displayed, it indicates that the sample size was inadequate to conduct the analysis. Statistically significant differences indicated by p-values: $p \le 0.05$.

Table 4. History of prior SARS-CoV-2 vaccination and/or infection of participants of the phase III immunobridging study at baseline

n (%)	AVX 705 (49.8)	AZ 712 (50.2)	p-Value
Prior infection, n (%)	33 (4.6)	38 (5.3)	0.57
Time (month) since last infection, mean (SD)	13.7 (7.3)	16 (8.7)	0.28
Number of prior vaccines, n (%)			
1	218 (30.92)	233 (32.72)	0.73
2	306 (43.40)	294 (41.29)	
3	169 (23.97)	169 (23.73)	
4	12 (1.70)	16 (2.24)	
Previous vaccination dose(s) received, n (%)			
AstraZeneca			
1	182 (25.81)	178 (25)	0.84
2	171 (24.25)	182 (25.56)	
3 or more	45 (6.38)	45 (6.32)	
Pfizer			
1	29 (4.11)	31 (4.35)	0.85
2	96 (13.61)	93 (13.06)	
3	3 (0.42)	2 (0.28)	
Cansino			
1	118 (16.73)	124 (17.41)	0.24
2	12 (1.70)	7 (0.98)	
Sputnik			
1	47 (6.66)	50 (7.02)	0.4
2	42 (5.95)	38 (5.33)	
3	13 (1.84)	8 (1.12)	
Sinovac			
1	15 (2.12)	24 (3.37)	0.25
2	28 (3.97)	28 (3.93)	
3	1 (0.14)	0	
Moderna			

n (%)	AVX 705 (49.8)	AZ 712 (50.2)	p-Value
1	32 (4.53)	23 (3.23)	0.12
2	4 (0.56)	9 (1.26)	0112
Novavax	()	- (- /	
1	2 (0.28)	4 (0.56)	0.62
2	4 (0.56)	3 (0.42)	
3	11 (1.56)	18 (2.52)	
Coronavac			
1	3 (0.42)	0	0.99
2	8 (1.13)	3 (0.42)	
Janssen			
1	2 (0.28)	3 (0.42)	0.99
2	3 (0.42)	3 (0.42)	
Curevac			
1	0	0	
2	0	2 (0.28)	NA

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation. Mann–Whitney U tests were conducted for the comparison for continous variables, and the Chi-Square test for categorical variables. In instances where a p-value is not displayed (NA), it indicates that the sample size was inadequate to conduct the analysis. Statistically significant differences indicated by p-values: $p \le 0.05$.

Table 5. AVX/COVID-12 vaccine meets WHO's non-inferiority criteria in comparison to

 AZ/ChAdOx-1-S neutralizing antibody titers at 14 days post-boosting

	Basal			
	AVX/COVID-12	AZ/ChAdOx-1- S	GM Ratio	P-Value
TOTAL Subjects	705	712		
GM of neutralizing antibody titers	767.5	836.5	0.92	0.23
CI	690.8 - 852.7	760.7 - 919.9	0.78 - 1.03	
Seroconverted participants	410	397		
GM	409.5	487.9	0.84	0.05
CI	359.9 - 465.9	433.3 - 549.3	0.70 - 1.00	
Non-seroconverted participants	295	315		
GM	1837.6	1650.3	1.11	0.20
CI	1631.5 - 2069.7	1467.3 - 1856.1	0.94 - 1.31	
	14 días			
	AVX	AZ	GM Ratio	
TOTAL Subjects	705	712		
GM	1305.2	1364.38	0.96	
CI	1210.8 - 1407.5	1260.7- 1476.5	0.85 - 1.06	
Seroconverted participants	410	397		

GM	1484.5	1763.1	0.84
CI	1342.8 -1641.1	1587.9 - 1957.6	0.72 - 0.97
Non-seroconverted participants	295	315	
GM	1091.5	987.6	1.11
CI	977.2 - 1219.2	883.8 -1103.6	0.94 - 1.29

Note: GM = Geometric Mean, CI = Confidence Interval, The GM ratio was calculated as GM AVX/COVID-12 / GM AZ/ChAdOx-1-S. The CIs were calculated using a t-Student test with the transforming variable on a natural logarithmic scale.

Table 6. Incidence of COVID-19 cases

Subjects in the study	Total 1,417	AVX/COVID-12 705 (49.8)	AZ/ChAdOx-1-S 712 (50.2)
Total follow-up time in days	255,143	127,120	128,023
Average time (SD) in days	180 (31.6)	180.3 (29.6)	179.8 (33.5)
COVID-19 cases (%) ¹	79 (5.5)	37 (5.3)	42 (6.3)
Incidence rate per 1000 days	0.30	0.29	0.32
1 an Damle Teatern vielves 0.50			

¹Log Rank Test: p-value = 0.58

SOC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Subjects		3120		936		4056		
Any AE	Total	800	(25.64)	193	(20.61)	993	(24.48)	0.001
	Mi	698	(22.37)	173	(18.48)	871	(21.47)	0.01
	Мо	108	(3.46)	21	(2.24)	129	(3.18)	0.06
	S	9	(0.28)	0	(0)	9	(0.22)	0.10
Skin and subcutaneous tissue disorders	Total	23	(0.73)	5	(0.53)	28	(0.69)	0.51
	Mi	17	(0.54)	5	(0.53)	22	(0.54)	0.96
	Мо	6	(0.19)	0	(0)	6	(0.14)	0.17
	S	0	(0)	0	(0)	0	(0)	
Erythema	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Papule	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
Itching	Mi	15	(0.48)	4	(0.42)	19	(0.46)	0.83
Itching	Мо	5	(0.16)	0	(0)	5	(0.12)	0.22
Nervous system disorders	Total	6	(0.19)	0	(0)	6	(0.14)	0.17
	Mi	5	(0.16)	0	(0)	5	(0.12)	0.22
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
	S	0	(0)	0	(0)	0	(0)	
Paresthesia	Mi	5	(0.16)	0	(0)	5	(0.12)	0.22
Paresthesia	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
General disorders and local events	Total	786	(25.19)	190	(20.29)	976	(24.06)	0.002
	Mi	685	(21.95)	170	(18.16)	855	(21.07)	0.01
	Мо	101	(3.23)	21	(2.24)	122	(3)	0.11
	S	9	(0.28)	0	(0)	9	(0.22)	0.10
Heat at the vaccination site	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Pain at the application site	Mi	3	(0.09)	0	(0)	3	(0.07)	0.34
Pain at the application site	Mi	655	(20.99)	165	(17.62)	820	(20.21)	0.02

Supplementary Table 1. Proportion of affected subjects by local adverse events of special interest at 7 days post-immunization

SOC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Pain at the injection site	Mo	98	(3.14)	21	(2.24)	119	(2.93)	0.15
Pain at the injection site	S	8	(0.25)	0	(0)	8	(0.19)	0.12
Edema at the injection site	Mi	4	(0.12)	1	(0.1)	5	(0.12)	0.87
Edema at the injection site	Мо	5	(0.16)	0	(0)	5	(0.12)	0.22
Redness at the injection site	Mi	28	(0.89)	9	(0.96)	37	(0.91)	0.85
Redness at the injection site	Мо	7	(0.22)	0	(0)	7	(0.17)	0.14
Redness at the injection site	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Hematoma at the injection site	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Swelling	Mi	4	(0.12)	2	(0.21)	6	(0.14)	0.55
Induration at the application site	Mi	11	(0.35)	3	(0.32)	14	(0.34)	0.88
Inflammation	Mi	13	(0.41)	1	(0.1)	14	(0.34)	0.15
Nerve injury at the injection site	Mi	0	(0)	2	(0.21)	2	(0.04)	0.009
Itching at the injection site	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Musculoskeletal and connective tissue disorders	Total	10	(0.32)	0	(0)	10	(0.24)	0.08
	Mi	6	(0.19)	0	(0)	6	(0.14)	0.17
	Мо	4	(0.12)	0	(0)	4	(0.09)	0.27
	S	0	(0)	0	(0)	0	(0)	
Pain in a limb	Mi	4	(0.12)	0	(0)	4	(0.09)	0.27
Pain in a limb	Мо	3	(0.09)	0	(0)	3	(0.07)	0.34
Discomfort in the extremities	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Discomfort in the extremities	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC: System Organ Class; PT: Preferred term; AE: Adverse Event; Mi: Mild; Mo: Moderate; S: Severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S. P-value calculated from comparison of proportions (Z-test)

Supplementary Table 2. Proportion of affected subjects by systemic adverse events of special interest at 7 days post-immunization

SOC Severity	AVX	%	AZ	%	Total	%	p-Value
--------------	-----	---	----	---	-------	---	---------

SOC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Subjects		3120		936		4056		
Any AE	Total	596	(19.1)	203	(21.68)	799	(19.69)	0.08
	Mi	496	(15.89)	183	(19.55)	679	(16.74)	0.008
	Мо	139	(4.45)	39	(4.16)	178	(4.38)	0.70
	S	16	(0.51)	2	(0.21)	18	(0.44)	0.22
Supplementary examinations	Total	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
	S	0	(0)	0	(0)	0	(0)	
High blood pressure elevation	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Infections and infestations	Total	2	(0.06)	0	(0)	2	(0.04)	0.43
	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
	S	0	(0)	0	(0)	0	(0)	
Oral herpes	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Oral herpes	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Cardiac disorders	Total	3	(0.09)	3	(0.32)	6	(0.14)	0.11
	Mi	2	(0.06)	3	(0.32)	5	(0.12)	0.05
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
	S	0	(0)	0	(0)	0	(0)	
Chest pain	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Palpitations	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Tachycardia	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Tachycardia	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Skin and subcutaneous tissue disorders	Total	6	(0.19)	2	(0.21)	8	(0.19)	0.89
	Mi	4	(0.12)	1	(0.1)	5	(0.12)	0.87
	Мо	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	S	1	(0.03)	0	(0)	1	(0.02)	0.58

OC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Rash	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Excessive sweating	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Excessive sweating	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Skin lesion	Мо	0	(0)	1	(0.1)	1	(0.02)	0.07
Hives	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Hives	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Reproductive and breast disorders	Total	3	(0.09)	1	(0.1)	4	(0.09)	0.92
	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
	S	0	(0)	0	(0)	0	(0)	
Polymenorrhea	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Polymenorrhea	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Heavy menstrual bleeding	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Menstrual disorders	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
letabolism and nutrition disorders	Total	0	(0)	1	(0.1)	1	(0.02)	0.07
	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Мо	0	(0)	0	(0)	0	(0)	
	S	0	(0)	0	(0)	0	(0)	
Decreased appetite	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
ar and labyrinth disorders	Total	2	(0.06)	1	(0.1)	3	(0.07)	0.67
	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Мо	0	(0)	1	(0.1)	1	(0.02)	0.07
	S	0	(0)	0	(0)	0	(0)	
Vertigo	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Vertigo	Мо	0	(0)	1	(0.1)	1	(0.02)	0.07
nmune system disorders	Total	2	(0.06)	0	(0)	2	(0.04)	0.43
	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Мо	0	(0)	0	(0)	0	(0)	

DC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	S	0	(0)	0	(0)	0	(0)	
Hypersensitivity	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
ervous system disorders	Total	270	(8.65)	98	(10.47)	368	(9.07)	0.08
	Mi	193	(6.18)	77	(8.22)	270	(6.65)	0.02
	Мо	69	(2.21)	21	(2.24)	90	(2.21)	0.95
	S	10	(0.32)	1	(0.1)	11	(0.27)	0.27
Headache	Mi	171	(5.48)	72	(7.69)	243	(5.99)	0.01
Headache	Мо	66	(2.11)	21	(2.24)	87	(2.14)	0.81
Headache	S	8	(0.25)	0	(0)	8	(0.19)	0.12
Dizziness	Mi	15	(0.48)	7	(0.74)	22	(0.54)	0.32
Dizziness	Мо	2	(0.06)	0	(0)	2	(0.04)	0.43
Migraine	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Paresthesia	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Drowsiness	Mi	11	(0.35)	1	(0.1)	12	(0.29)	0.22
Drowsiness	Мо	3	(0.09)	0	(0)	3	(0.07)	0.34
Drowsiness	S	4	(0.12)	1	(0.1)	5	(0.12)	0.87
Tremor	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
astrointestinal disorders	Total	62	(1.98)	21	(2.24)	83	(2.04)	0.62
	Mi	47	(1.5)	19	(2.02)	66	(1.62)	0.26
	Мо	15	(0.48)	2	(0.21)	17	(0.41)	0.26
	S	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Diarrhea	Mi	25	(0.8)	10	(1.06)	35	(0.86)	0.43
Diarrhea	Мо	8	(0.25)	1	(0.1)	9	(0.22)	0.39
Diarrhea	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Abdominal distension	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Abdominal pain	Mi	5	(0.16)	1	(0.1)	6	(0.14)	0.70
Abdominal pain	Мо	2	(0.06)	0	(0)	2	(0.04)	0.43
Abdominal pain	S	0	(0)	1	(0.1)	1	(0.02)	0.07

DC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Upper abdominal pain	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Constipation	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Nausea	Mi	4	(0.12)	6	(0.64)	10	(0.24)	0.005
Nausea	Мо	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Odynophagia	Mi	12	(0.38)	4	(0.42)	16	(0.39)	0.85
Odynophagia	Мо	4	(0.12)	0	(0)	4	(0.09)	0.27
Vomiting	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
Vomiting	Мо	0	(0)	1	(0.1)	1	(0.02)	0.07
Aphthous ulcer	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
eneral disorders and administration site alterations	Total	255	(8.17)	110	(11.75)	365	(8.99)	0.0008
	Mi	204	(6.53)	99	(10.57)	303	(7.47)	0.000
	Мо	50	(1.6)	14	(1.49)	64	(1.57)	0.81
	S	7	(0.22)	0	(0)	7	(0.17)	0.14
Asthenia	Mi	21	(0.67)	3	(0.32)	24	(0.59)	0.21
Asthenia	Мо	2	(0.06)	0	(0)	2	(0.04)	0.43
Chest pain	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Flu-like illness	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Flu-like illness	Мо	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Influenza-like illness	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Shivering	Mi	8	(0.25)	16	(1.7)	24	(0.59)	0.000
Shivering	Мо	3	(0.09)	1	(0.1)	4	(0.09)	0.92
Shivering	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Fatigue	Mi	109	(3.49)	29	(3.09)	138	(3.4)	0.55
Fatigue	Мо	30	(0.96)	9	(0.96)	39	(0.96)	0.99
Fatigue	S	6	(0.19)	0	(0)	6	(0.14)	0.17
Peripheral coldness	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Hyperthermia	Mi	5	(0.16)	3	(0.32)	8	(0.19)	0.33
Inflammation	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58

OC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Discomfort	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Discomfort	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
General discomfort	Mi	19	(0.6)	9	(0.96)	28	(0.69)	0.25
General discomfort	Мо	4	(0.12)	1	(0.1)	5	(0.12)	0.87
Chest tightness	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Pyrexia	Mi	50	(1.6)	51	(5.44)	101	(2.49)	0.000
Pyrexia	Мо	14	(0.44)	4	(0.42)	18	(0.44)	0.93
Pyrexia	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Decreased thirst	Mi	0	(0)	1	(0.1)	1	(0.02)	0.06
Feeling cold	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
lusculoskeletal and connective tissue disorders	Total	139	(4.45)	51	(5.44)	190	(4.68)	0.20
	Mi	98	(3.14)	43	(4.59)	141	(3.47)	0.03
	Мо	41	(1.31)	8	(0.85)	49	(1.2)	0.25
	S	3	(0.09)	0	(0)	3	(0.07)	0.34
Arthralgia	Mi	29	(0.92)	21	(2.24)	50	(1.23)	0.001
Arthralgia	Мо	10	(0.32)	4	(0.42)	14	(0.34)	0.62
Arthralgia	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Back pain	Mi	5	(0.16)	2	(0.21)	7	(0.17)	0.72
Back pain	Мо	3	(0.09)	0	(0)	3	(0.07)	0.34
Ligament sprain	Мо	0	(0)	1	(0.1)	1	(0.02)	0.07
Muscle spams	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Myalgia	Mi	68	(2.17)	24	(2.56)	92	(2.26)	0.48
Myalgia	Мо	31	(0.99)	4	(0.42)	35	(0.86)	0.10
Myalgia	S	2	(0.06)	0	(0)	2	(0.04)	0.43
Discomfort in limbs	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
ocular disorders	Total	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	S	0	(0)	0	(0)	0	(0)	
Allergic conjunctivitis	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Photopsia	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Psychiatric disorders	Total	5	(0.16)	3	(0.32)	8	(0.19)	0.33
	Mi	5	(0.16)	3	(0.32)	8	(0.19)	0.33
	Мо	0	(0)	0	(0)	0	(0)	
	S	0	(0)	0	(0)	0	(0)	
Mood changes	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Confusional state	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Insomnia	Mi	1	(0.03)	2	(0.21)	3	(0.07)	0.07
Irritability	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
Respiratory, thoracic and mediastinal disorders	Total	111	(3.55)	24	(2.56)	135	(3.32)	0.13
	Mi	88	(2.82)	23	(2.45)	111	(2.73)	0.55
	Мо	24	(0.76)	3	(0.32)	27	(0.66)	0.13
	S	3	(0.09)	0	(0)	3	(0.07)	0.34
Asthma	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Nasal congestion	Mi	12	(0.38)	3	(0.32)	15	(0.36)	0.77
Nasal congestion	Мо	2	(0.06)	0	(0)	2	(0.04)	0.43
Dyspnea	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
Dyspnea	Мо	0	(0)	1	(0.1)	1	(0.02)	0.07
Dyspnea	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Pharyngolaryngeal pain	Mi	9	(0.28)	2	(0.21)	11	(0.27)	0.69
Pharyngolaryngeal pain	Мо	7	(0.22)	1	(0.1)	8	(0.19)	0.47
Pharyngolaryngeal pain	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Hiccups	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Allergic rhinitis	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Rhinorrhea	Mi	61	(1.95)	14	(1.49)	75	(1.84)	0.36
Rhinorrhea	Мо	15	(0.48)	1	(0.1)	16	(0.39)	0.10

SOC	Coverity		0/	. 7	0/	Tatal	0/	
PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Rhinorrhea	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Cough	Mi	17	(0.54)	7	(0.74)	24	(0.59)	0.47
Cough	Мо	6	(0.19)	1	(0.1)	7	(0.17)	0.58
Cough	S	1	(0.03)	0	(0)	1	(0.02)	0.58
Productive cough	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Vascular disorders	Total	5	(0.16)	1	(0.1)	6	(0.14)	0.70
	Mi	4	(0.12)	1	(0.1)	5	(0.12)	0.87
	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
	S	0	(0)	0	(0)	0	(0)	
Flushing	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
Flushing	Мо	1	(0.03)	0	(0)	1	(0.02)	0.58
Hypertensive crisis	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Hypertension	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC: System Organ Class; PT: Preferred term; AE: Adverse Event; Mi: Mild; Mo: Moderate; S: Severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S. P-value calculated from comparison of proportions (Z-test).

Supplementary Table 3. Percentage of total, CD4⁺ and CD8⁺ T cells producing IFN-γ in response to fraction 1 of spike protein stimulation

Vacuna	cuna AVX/COVID-12					AZ/ChAdOx-1-S					
Medición	Basal	Day 14	Day 90	Day 180	Basal	Day 14	Day 90	Day 180			
Sujetos	53	53	44	34	50	50	40	33			
				T Lymphocytes							
Mediana	0.082	0.076	0.079	0.05 *	0.087	0.098	0.071	0.036 *			
RIQ	0.059 - 0.134	0.059 - 0.152	0.059 - 0.107	0.027 - 0.083	0.066 - 0.129	0.07 - 0.144	0.049 - 0.093	0.021 - 0.077			
			CE	04 ⁺ T Lymphocyte	S						
Mediana	0.041	0.051	0.045	0.034	0.05	0.05	0.041	0.0319 *			
RIQ	0.028 - 0.075	0.035 - 0.087	0.029 - 0.062	0.021 - 0.084	0.027 - 0.079	0.033 - 0.075	0.028 - 0.072	0.021 - 0.045			
			CE	08 ⁺ T Lymphocyte	S						
Mediana	0.015	0.019	0.017	0.017	0.013	0.021 *	0.016	0.014			
RIQ	0.008 - 0.026	0.011 - 0.033	0.011 - 0.033	0.009 - 0.022	0.006 - 0.033	0.01 - 0.057	0.009 - 0.03	0.006 - 0.023			

IQR: Interquartile range p25-p75. p-values: *<= 0.05 for intra-group comparisons using the Wilcoxon signed-rank test.

* Statistically significant increase compared to baseline values, * Statistically significant decrease compared to baseline values.